

bio  scrip



2013
Therapeutic Formulary

Table of Contents

| Section | Page |
|--------------------------------------|-------------|
| INTRODUCTION | I-1 |
| ANTI-INFECTIVE AGENTS | 1 |
| BIOLOGICALS | 3 |
| ANTINEOPLASTICS | 3 |
| ENDOCRINE & METABOLIC DRUGS..... | 4 |
| CARDIOVASCULAR AGENTS | 6 |
| RESPIRATORY AGENTS..... | 9 |
| GASTROINTESTINAL AGENTS..... | 10 |
| GENITOURINARY | 11 |
| CENTRAL NERVOUS SYSTEM DRUGS | 12 |
| ANALGESICS & ANESTHETICS..... | 12 |
| NEUROMUSCULAR DRUGS | 14 |
| NUTRITIONAL PRODUCTS..... | 15 |
| HEMATOLOGICAL AGENTS | 16 |
| BEHAVIORAL HEALTH AGENTS | 17 |
| TOPICAL PRODUCTS..... | 17 |
| MISCELLANEOUS PRODUCTS | 19 |
| PRIOR AUTHORIZATION GUIDELINES | PA-1 |
| INDEX..... | IDX-1 |

BioScrip/Jai Medical Systems Managed Care Organization 2013 Therapeutic Formulary

This formulary describes the circumstances under which pharmacies participating in a particular medical benefit program will be reimbursed for medications dispensed to patients covered by the program. This formulary does not:

- a) Require or prohibit the prescribing or dispensing of any medication.
- b) Substitute for the independent professional judgment of the physician or pharmacist.
- c) Relieve the physician or pharmacist of any obligation to the patient or others.

I. Non-Prescription Medication Policy

This program does not cover most over-the-counter medications (OTC). The only exceptions to this policy are listed within the program formulary. Furthermore, an OTC medication can be reimbursed only if it is written on a valid prescription form by a licensed prescriber.

II. Unapproved Use of Formulary Medication

Medication coverage under this program is limited to non-experimental indications as approved by the FDA. Other indications, which are accepted as safe and effective by the balance of current medical opinion and available scientific evidence, may also be covered. BioScrip, utilizing the procedures outlined in section IV, will make decisions about reimbursement for these other indications. Experimental, investigational drugs, and drugs used for cosmetic purposes are not eligible for coverage.

III. Prior Authorization Procedure

To promote the most appropriate utilization of selected high risk and/or high cost medication, a prior authorization procedure has been created. The criteria for this system has been established by the BioScrip/Jai Medical Systems Managed Care Organization program with input from pharmacists and physician practitioners and in consideration of the available medical literature. The Pharmacy and Therapeutics Committee will have final approval responsibility for this list. In order for a dispensed prior authorization medication to be reimbursed to the pharmacy, the patient's prescribing physician must apply for pre-authorization for a specific patient and drug. The physician may phone or fax BioScrip to request prior authorization:

**BioScrip
Prior Authorization Desk
2787 Charter Street
Columbus, Ohio 43228
(800) 555-8513
(800) 583-6010 (fax)**

Please have patient information, including member I.D. number, complete diagnosis, medication history, and current medications readily available.

These phone lines are dedicated to physicians making requests for prior authorization medication and non-formulary items. Members cannot be assisted if they call the prior-authorization toll-free number. For emergent requests for drugs requiring prior-authorization, a response will be made within 24 hours. For Non-Emergent requests for drugs requiring prior-authorization, a response will be provided within 2 business days of receipt of information. If the necessary information is not received, this process could take up to 7 calendar days. If the request is approved, information in the on-line pharmacy claims processing system will be changed to allow the specific patient to receive this specific drug. A prior authorization number will be issued to the prescribing physician and is to be clearly written on the top of the prescription to inform the dispensing pharmacist of the approval. This number is for identification purposes only and does not need to be submitted for adjudication to occur. If the

request is denied, information about the denial will be provided to the prescribing physician along with the patient and the patient's PCP. In addition to those products that require prior authorization all injectables (except Depo-Provera, Insulin, Glucagon Kit, and Epi-Pen) require prior approval. Questions about injectable drugs administered by homehealth or healthcare providers should be directed to BioScrip at 800-555-8513.

IV. Unique Patient Needs Non-Formulary Medication

This formulary attempts to provide appropriate and cost effective drug therapy to all participants in the BioScrip/Jai Medical Systems Managed Care Organization program. If a patient requires medication that is not covered by the formulary, a request can be made for payment for the non-covered item. It is anticipated that such exceptions will be rare, and that formulary medications will be appropriate to treat the vast majority of medical conditions. Requests for non-formulary medications should be made in writing (on the "Medical Necessity form" if possible) and mailed or faxed to:

**BioScrip
Medical Necessity Desk
2787 Charter Street
Columbus, Ohio 43228
(800) 555-8513
(800) 583-6010 (fax)**

Appropriate documentation must be provided to support the request. For emergent requests for drugs requiring prior-authorization, a response will be made within 24 hours. For Non-Emergent requests for drugs requiring prior-authorization, a response will be provided within 2 business days of receipt of information. If the necessary information is not received, this process could take up to 7 calendar days. Approval of non-formulary items will be based upon criteria developed by the Pharmacy and Therapeutics Committee of Jai Medical Systems Managed Care Organization and BioScrip.

Physicians are expected to comply with this formulary when prescribing medication for those patients covered by the BioScrip/Jai Medical Systems Managed Care Organization plan. If a pharmacist receives a prescription for a non-formulary medication, the pharmacist should attempt to contact the prescribing physician to request a change to a product included in this formulary guide.

The pharmacy will not be reimbursed for non-formulary medications. **In an emergency situation outside of BioScrip’s regular business hours, where the physician cannot be contacted, the pharmacist is authorized to dispense a 72 hour emergency supply of a medication, unless the medication is classified as a DESI, LTE or specifically excluded drug category (see section VI) product.**

The pharmacist should contact BioScrip’s Help Desk at (800) 213-5640 during regular business hours to arrange for reimbursement for the emergency supply.

V. Newly Marketed Products

Newly marketed drug products will not normally be placed on the formulary during their first year on the market. Exceptions to this rule will be made on a case by case basis using the medical necessity procedure.

VI. Specific Exclusions

The following drug categories are not part of the BioScrip/Jai Medical Systems Managed Care Organization formulary and are not covered by the 72-hour emergency supply reimbursement policy:

- Antiobesity products
- Blood and blood plasma
- Cosmetic drugs
- Cough and cold products (except those listed in formulary)
- DESI drugs
- Diagnostic products (except those listed in formulary)
- Erectile Dysfunction agents
- Medical supplies and durable medical equipment (except certain diabetic supplies)
- Most vitamins
- Nutritional and dietary supplements
- Research drugs
- Topical minoxidil

VII. Fee-For-Service Carve-outs

In addition to the above exclusions, the following are also excluded from the formulary, and are covered by the Maryland Department of Health and Mental Hygiene:

HIV drugs

Mental Health drugs (refer to Section VIII. Behavioral Health Medication Policy)

VIII. Behavioral Health Medication Policy

Please refer to the Maryland Department of Health and Mental Hygiene's Mental Health Formulary for a complete listing of behavioral health medications. Any behavioral health medications that are covered by Jai Medical Systems Managed Care Organization are listed in the prescription formulary.

- Kapvay – For recipients 6 -17 years old, Kapvay is part of the mental health formulary and billed fee-for-service. For individuals not in this age range, Kapvay continues to be a part of the MCO pharmacy benefit.
- Intuniv – For recipients 6 -17 years old, Intuniv is part of the mental health formulary and billed fee-for-service. For individuals not in this age range, Intuniv continues to be a part of the MCO pharmacy benefit.

IX. Mandatory Generic Substitution & Therapeutic Interchange

Generic substitution is mandatory when a generic equivalent is available. All branded products that have 3 or more generic equivalents available will be reimbursed at the maximum allowable cost. No other therapeutic interchange is permitted.

X. Specialty Medications

Effective 02/01/2010, specialty medications will be covered under the pharmacy benefit for Jai Medical Systems. All requests will undergo prior authorization review when available drug specific prior authorization criteria will apply. When prior authorization criteria does not exist the request will be reviewed for FDA approved indications according to Jai Medical Systems' approved medical necessity review process. All specialty drug requests should contain the following:

- Drug name, strength, dose and quantity requested
- Diagnosis for use
- Any previous drug therapies tried and failed
- Any additional clinical information pertinent to the drug review

For emergent specialty drug requests, a decision will be made within 24 hours. For non-emergent specialty drug requests, a response will be provided within 2 business days of receipt of the clinical information. If the necessary information is not received, this process could take up to 7 calendar days.

XI. General Parameters

- Valid DEA and NPI numbers are required. Physicians without numbers should contact BioScrip at 1-800-230-8189.
- Refill too soon - 75% of the day's supply must elapse before the prescription can be refilled.
- Maximum allowable quantity is a 30 days supply. The quantity limit on most medications is a 400-unit maximum limit per month. Most narcotics have individualized quantity and dosage form limitations, which are listed on page 13 of the formulary. If necessary, a healthcare provider may request a quantity override by contacting BioScrip's Prior Authorization Department. The Prior Authorization procedure can be found on page I-2.
- No vacation fills are allowed.
- No overrides for lost or stolen prescriptions are allowed.

XII. Where to Call?

PHYSICIANS

Formulary Questions:

BioScrip (800) 555-8513

Medical Necessity:

BioScrip (800) 555-8513

Prior Authorization:

BioScrip (800) 555-8513

Provider Relations:

Jai Medical Systems

Managed Care Organization, Inc. (888) JAI-1999

PHARMACISTS

Provider Network Questions:

BioScrip (800) 230-8187

Provider Relations:

BioScrip (800) 213-5640

XIII. Abbreviations

Providers are encouraged to prescribe generically available drugs whenever possible and to prescribe first-line lower cost options when appropriate. Drugs are ranked by cost with the following abbreviations:

| | | |
|------------|---|---|
| * | = | This product has a MAC price attached to some or all strengths. |
| \$ | = | Cost per Rx is <\$20 |
| \$\$ | = | Cost per Rx is <\$40 |
| \$\$\$ | = | Cost per Rx is \$40 - \$80 |
| \$\$\$\$ | = | Cost per Rx is \$80 - \$160 |
| \$\$\$\$\$ | = | Cost per Rx is >\$160 |

XIV. Reference

The formulary is now available online at e-pocrates. This is updated monthly and will have the most up-to-date information. Registration is free and available at:

www.epocrates.com

Links to pdf copies of the most recent printed versions of all Maryland Medicaid Managed Care Organization's formularies can be found on the website listed below:

www.mdmahealthchoicerox.com

A link to a pdf copy of the Jai Medical Systems formulary is also available in the Providers section of our homepage:

www.jaimedicalsystems.com

XV. Copays

Currently, there is no copay for active members of Jai Medical Systems Members Managed Care Organization, Inc.'s HealthChoice Program. For all members of Jai Medical Systems' Primary Adult Care program there is a \$2.50 copay for all generic medications and a \$7.50 copay for brand medications (brand status is determined by Medispan).

XVI. Step Therapy

Jai Medical Systems offers Step therapy for Advair and Symbicort. For members with a current approved prior authorization, claims will continue to process as long as the member has filled for that medication within the last 3 months. No yearly renewal will be needed for compliant members. Prior authorization will be required for members new to the plan, new to therapy, or with no claim history of that medication within the last 3 months.

Prescription Formulary

BioScrip/Jai Medical Systems Therapeutic Formulary

Generic Name

Brand Name

Annotation

I. ANTI-INFECTIVE AGENTS

PENICILLINS

| | | |
|----------------------------|------------|---------------------|
| \$ Amoxicillin* | AMOXIL | <i>no chewables</i> |
| \$ Ampicillin* | AMPICILLIN | |
| \$ Penicillin G Benzathine | BICILLIN | |
| \$ Penicillin V Potassium* | PEN VEE K | |

Penicillinase-resistant

| | | |
|--------------------------|----------------------|--|
| \$ Dicloxacillin Sodium* | DICLOXACILLIN SODIUM | |
| \$ Oxacillin* | OXACILLIN | |

| | | |
|------------------------|--------------------|--|
| \$ Cloxacillin Sodium* | CLOXACILLIN SODIUM | |
|------------------------|--------------------|--|

Prior Authorization Required

Penicillin Combinations

| | | |
|-----------------------|-----------|---------------------|
| \$\$\$ Amox & K Clav* | AUGMENTIN | <i>no chewables</i> |
|-----------------------|-----------|---------------------|

CEPHALOSPORINS

Cephalosporins - 1st Generation

| | | |
|----------------|------------|-------------------|
| \$ Cephalexin* | KEFLEX | <i>no tablets</i> |
| \$ Cephradine* | CEPHRADINE | |

Cephalosporins - 2nd Generation

| | | |
|--------------------|--------------------|--|
| \$\$ Cefaclor* | CEFACTOR | |
| \$\$\$ Cefprozil* | CEFZIL | |
| \$\$\$ Cefuroxime* | CEFTIN | <i>oral tablets only covered for children under 12 yrs old</i> |
| \$\$\$ Loracarbef | LORABID SUSPENSION | |

Cephalosporins - 3rd Generation

| | | |
|---------------------|----------|-------------------|
| \$ Cefixime | SUPRAX | <i>QL = 1 tab</i> |
| \$\$\$ Ceftriaxone* | ROCEPHIN | |

| | | |
|-----------------|---------|------------------------|
| \$\$\$ Cefdinir | OMNICEF | <i>suspension only</i> |
|-----------------|---------|------------------------|

Prior Authorization Required

MACROLIDE ANTIBIOTICS

Erythromycins

| | | |
|---------------------------------|-----------------------|--|
| \$ Erythromycin Base* | ERY-TAB | |
| \$ Erythromycin Estolate* | ERYTHROMYCIN ESTOLATE | |
| \$ Erythromycin Ethylsuccinate* | E.E.S. | |
| \$ Erythromycin Stearate* | ERYTHROCIN | |

Lincomycins

| | | |
|-------------------|---------|--|
| \$\$ Clindamycin* | CLEOCIN | |
|-------------------|---------|--|

Misc. Macrolide Antibiotics

| | | |
|---------------------------------|-----------|----------------------------------|
| \$\$ Azithromycin* | ZITHROMAX | |
| \$\$\$ Azithromycin suspension* | ZITHROMAX | <i>QL = 1 single dose packet</i> |
| \$\$\$ Clarithromycin* | BIAXIN | |

TETRACYCLINES

| | | |
|------------------|------------|-------------------|
| \$ Doxycycline* | VIBRAMYCIN | |
| \$ Tetracycline* | SUMYCIN | <i>no tablets</i> |

FLUOROQUINOLONES

| | | |
|------------------------|----------|--------------------------|
| \$\$\$ Ciprofloxacin* | CIPRO | |
| \$\$\$\$ Levofloxacin* | LEVAQUIN | |
| \$\$\$ Moxifloxacin | AVELOX | <i>QL 14 per 30 days</i> |

Prior Authorization Required

BioScrip/Jai Medical Systems Therapeutic Formulary

| <u>Generic Name</u> | <u>Brand Name</u> | <u>Annotation</u> |
|---|----------------------------|---|
| <u>ANTIMALARIAL</u> | | |
| \$ Chloroquine* | ARALEN | <i>no 500mg tabs</i> |
| \$ Hydroxychloroquine* | PLAQUENIL | |
| <u>ANTHELMINTIC</u> | | |
| \$\$ Albendazole | ALBENZA | <i>OTC product</i> |
| \$\$ Mebendazole* | MEBENDAZOLE | |
| \$\$\$\$ Pyrantel Pamoate* | PIN - X | |
| <u>AMINOGLYCOSIDES</u> | | |
| \$ Gentamicin Sulfate* | GARAMYCIN | <i>tablets only</i> |
| \$ Neomycin Sulfate* | NEOMYCIN | |
| <u>SULFONAMIDES</u> | | |
| \$ Erythromycin/Sulfisoxazole* | ERYTHROMYCIN/SULFISOXAZOLE | <i>no EN tabs</i> |
| \$ Sulfadiazine* | SULFADIAZINE | |
| \$ Sulfasalazine* | AZULFIDINE | |
| \$ Sulfisoxazole* | GANTRISIN | |
| \$ Trimethoprim/Sulfamethoxazole* | BACTRIM / DS | |
| <u>ANTIMYCOBACTERIAL AGENTS</u> | | |
| \$\$\$ Cycloserine | SEROMYCIN | |
| \$\$\$\$ Ethambutol* | MYAMBUTOL | |
| \$\$\$ Ethionamide | TRECTOR | |
| \$ Isoniazid* | ISONIAZID | |
| \$\$\$\$ Pyrazinamide* | PYRAZINAMIDE | |
| \$\$\$\$ Rifabutin | MYCOBUTIN | |
| \$\$\$\$\$ Rifampin* | RIFADIN | |
| <u>MISC. ANTIINFECTIVES</u> | | |
| \$ Metronidazole* | FLAGYL | |
| \$ Trimethoprim* | PROLOPRIM | |
| <i>Leprostatics</i> | | |
| \$ Dapsone* | DAPSONE | |
| <u>ANTIFUNGALS</u> | | |
| \$ Griseofulvin Microsize | GRIFULVIN V | |
| \$ Griseofulvin Ultramicronsize | GRIS-PEG | |
| \$ Nystatin* | MYCOSTATIN | |
| <i>Imidazole-Related Antifungals</i> | | |
| \$ Ketoconazole* | NIZORAL | <i>OTC product</i> |
| \$ Miconazole* | MONISTAT | |
| \$\$ Terbinafine* | LAMISIL | |
| \$\$ Itraconazole* | SPORANOX | |
| Prior Authorization Required | | |
| <i>Triazoles</i> | | |
| \$ Fluconazole* | DIFLUCAN | |
| Prior Authorization Required (requires PA after 1 x 150mg dispensed) | | |
| <u>ANTIVIRAL</u> | | |
| <i>Neuraminidase Inhibitors</i> | | |
| \$\$ Oseltamivir Phosphate | TAMIFLU | <i>QL=1 course of treatment per calendar year</i> |
| \$\$ Zanamivir | RELENZA | <i>QL=1 course of treatment per calendar year</i> |
| <i>CMV Agents</i> | | |
| \$\$\$\$ Ganciclovir* | CYTOVENE | |

BioScrip/Jai Medical Systems Therapeutic Formulary

Generic Name

Brand Name

Annotation

Hepatic Agents

| | | |
|-------------------------------------|---------------------|--|
| \$\$\$\$\$ Boceprevir | VICTRELIS | |
| \$\$\$\$\$ Peginterferon | PEG-INTRON, PEGASYS | |
| \$\$\$\$\$ Ribavirin* | REBETOL | |
| \$\$\$\$\$ Telaprevir | INCIVEK | |
| Prior Authorization Required | | |

Herpes Agents

| | | |
|-------------------|-----------|-----------------|
| \$\$ Amantadine* | SYMMETREL | |
| \$\$\$ Acyclovir* | ZOVIRAX | PA for ointment |

ANTIMALARIAL

| | | |
|------------------|----------|--|
| \$ Pyrimethamine | DARAPRIM | |
|------------------|----------|--|

II. BIOLOGICALS

ANTISERA

Antiviral Monoclonal Antibodies

| | | |
|-------------------------------------|---------|--|
| \$\$\$\$\$ Palivizumab | SYNAGIS | |
| Prior Authorization Required | | |

III. ANTINEOPLASTICS

ANTINEOPLASTICS

Alkylating Agents

| | | |
|---------------------|---------|--|
| \$\$\$\$\$ Busulfan | MYLERAN | |
|---------------------|---------|--|

Nitrogen Mustards

| | | |
|------------------------------|----------|--|
| \$\$\$\$\$ Chlorambucil | LEUKERAN | |
| \$\$\$\$\$ Cyclophosphamide* | CYTOXAN | |
| \$\$\$\$\$ Melphalan | ALKERAN | |

Nitrosoureas

| | | |
|----------------------|-------|--|
| \$\$\$\$\$ Lomustine | CEENU | |
|----------------------|-------|--|

Antimetabolites

| | | |
|----------------------------|------------|----------------------|
| \$\$\$\$\$ Capecitabine | XELODA | |
| \$\$\$ Fluorouracil* | EFUDEX | 2% and 5% cream only |
| \$\$\$\$\$ Mercaptopurine* | PURINETHOL | |
| \$\$\$\$\$ Methotrexate* | RHEUMATREX | |
| \$\$\$\$\$ Thioguanine | TABLOID | |

Progestins-Antineoplastic

| | | |
|---------------------|--------|--|
| \$\$\$\$ Megestrol* | MEGACE | |
|---------------------|--------|--|

Antiandrogens

| | | |
|-----------------------|-----------|--|
| \$\$\$\$\$ Flutamide* | FLUTAMIDE | |
|-----------------------|-----------|--|

Aromatase Inhibitors

| | | |
|-----------------------|--------|--|
| \$\$\$\$\$ Letrozole* | FEMARA | |
|-----------------------|--------|--|

Antineoplastic Hormones Misc.

| | | |
|-------------------------------------|----------|--|
| \$\$\$\$ Tamoxifen* | NOLVADEX | |
| \$\$\$\$\$ Leuprolide | LUPRON | |
| Prior Authorization Required | | |

Mitotic Inhibitors

| | | |
|---------------------|---------|--|
| \$\$\$\$ Etoposide* | VEPESID | |
|---------------------|---------|--|

BioScrip/Jai Medical Systems Therapeutic Formulary

| <u>Generic Name</u> | <u>Brand Name</u> | <u>Annotation</u> |
|-------------------------------------|-------------------|-------------------|
| <i>Antineoplastics Misc.</i> | | |
| \$\$\$\$ Erlotinib | TARCEVA | |
| \$\$\$\$ Hydroxyurea* | HYDREA | |
| \$\$\$\$ Mitotane | LYSODREN | |
| \$ Procarbazine | MATULANE | |
| \$\$\$\$ Sorafenib | NEXAVAR | |
| \$\$\$\$ Interferon Alfa-2A | ROFERON-A | |
| \$\$\$\$ Interferon Alfa-2B | INTRON-A | |
| \$\$\$\$ Interferon Alfa-n3 | ALFERON N | |
| \$\$\$\$ Interferon Beta-1a | AVONEX | |
| \$\$\$\$ Interferon Beta-1a | REBIF | |
| \$\$\$\$ Interferon Beta-1b | BETASERON | |
| \$\$\$\$ Glatiramer acetate | COPAXONE | |
| Prior Authorization Required | | |

IV. ENDOCRINE & METABOLIC DRUGS

CORTICOSTEROIDS

Glucocorticosteroids

| | | |
|-------------------------------|---------------|---------------------|
| \$ Cortisone* | CORTISONE | |
| \$ Dexamethasone* | DEXAMETHASONE | <i>no dose paks</i> |
| \$ Hydrocortisone* | CORTEF | |
| \$ Methylprednisolone* | MEDROL | <i>no dose paks</i> |
| \$ Prednisone* | PREDNISON | |
| \$ Prednisolone* | PRELONE | |
| \$ Prednisolone Na Phosphate* | PEDIAPRED | |

Mineralocorticoids

| | | |
|---------------------|----------|--|
| \$ Fludrocortisone* | FLORINEF | |
|---------------------|----------|--|

ANDROGEN-ANABOLIC

Androgens

| | | |
|---------------------------|---------|--|
| \$\$\$ Methyltestosterone | ANDROID | |
| \$\$\$ Danazol* | DANAZOL | |

ESTROGENS

| | | |
|----------------------------|----------|--|
| \$ Estradiol* | ESTRACE | |
| \$\$ Esterified Estrogens | MENEST | |
| \$\$ Estrogens, Conjugated | PREMARIN | |
| \$\$\$ Estradiol Patch* | CLIMARA | |

Estrogen Combinations

| | | |
|--|---------|--|
| \$\$ Conjugated Estrogens & Medroxyprogesterone* | PREMPRO | |
|--|---------|--|

CONTRACEPTIVES

Progestin

| | | |
|-----------------------|---------------|--|
| \$\$\$ Norethindrone* | ERRIN, CAMILA | |
|-----------------------|---------------|--|

Combinations

| | | |
|--|--------------------------------|---------------------------|
| \$\$ Desogest/Eth Est & Ethin Estradiol* | KARIVA | |
| \$\$ Desogestral & Ethinyl Estradiol* | APRI, ORTHOCEPT | |
| \$\$ Drospirenone & Ethinyl Estradiol* | YASMIN | |
| \$\$ Drospirenone & Ethinyl Estradiol* | YAZ | |
| \$\$ Ethynodiol Diacet & Eth Estrad* | ZOVIA | |
| \$\$\$ Etonogestrel-Ethinyl Estradiol | NUVARING | <i>QL= 1 ring / month</i> |
| \$\$ Levonorgestrel & Eth Estradiol* | AVIANE, LEVORA | |
| \$\$ Norethindrone & Eth Estradiol* | NECON, MICROGESTIN FE, NORTREL | |
| \$\$ Norgestrel & Ethinyl Estradiol* | CRYSELLE | |
| \$\$ Norgestimate & Ethinyl Estradiol* | SPRINTEC | |
| \$\$\$ Norelgestromin-Ethinyl Estradiol | ORTHO EVRA PATCH | |

Triphasic

| | | |
|--|---|--|
| \$\$ Levonorgestrel-Eth Estradiol* | TRIVORA | |
| \$\$ Norethindrone-Ethinyl Estrad* | NORTREL 7/7/7, NECON 7/7/7, TRI-NORINYL | |
| \$\$\$ Norgestimate-Ethinyl Estradiol* | ORTHO TRI-CYCLEN | |
| \$\$\$ Norgestimate-Ethinyl Estradiol | ORTHO TRI-CYCLEN LO | |

BioScrip/Jai Medical Systems Therapeutic Formulary

| <u>Generic Name</u> | <u>Brand Name</u> | <u>Annotation</u> |
|--|--------------------|--------------------------|
| <u>PROGESTINS</u> | | |
| \$ Medroxyprogesterone* | PROVERA | tabs only / females only |
| \$\$\$ Medroxyprogesterone Depot* | DEPO-PROVERA | 150mg inj. only |
| \$ Norethindrone* | AYGESTIN | |
| <u>EMERGENCY CONTRACEPTIVE</u> | | |
| \$\$ Levonorgestrel* | PLAN-B | 1 kit/month // 3 kits/yr |
| <u>ANTIDIABETIC</u> | | |
| <i>Thiazolidinediones/Combination</i> | | |
| \$\$ Pioglitazone* | ACTOS | QL = 30 tabs / month |
| \$\$\$ Pioglitazone-Glimepiride | DUETACT | QL = 30 tabs / month |
| \$\$\$ Pioglitazone-Metformin | ACTOPLUS MET | QL = 30 tabs / month |
| \$ Rosiglitazone Maleate | AVANDIA | QL = 30 tabs / month |
| \$\$ Rosiglitazone Maleate-Metformin | AVANDAMET | QL = 30 tabs / month |
| \$\$ Rosiglitazone Maleate-Glimepiride | AVANDARYL | QL = 30 tabs / month |
| Prior Authorization Required | | |
| <i>Human Insulin</i> | | |
| \$ Insulin Aspart | NOVOLOG | |
| \$ Insulin Isophane | HUMULIN N | |
| \$ Insulin Isophane | NOVOLIN N | |
| \$ Insulin Lispro | HUMALOG | |
| \$ Insulin Reg & Isophane | HUMULIN 50/50 | |
| \$ Insulin Reg & NPH | HUMULIN 70/30 | |
| \$ Insulin Reg & NPH | NOVOLIN 70/30 | |
| \$ Insulin Regular | HUMULIN R | |
| \$ Insulin Regular | NOVOLIN R | |
| \$\$ Insulin Glargine | LANTUS | |
| <i>Sulfonylureas</i> | | |
| \$ Glimepiride* | AMARYL | |
| \$\$ Glipizide* | GLUCOTROL/XL | |
| \$\$ Glyburide* | DIABETA, GLYNASE | |
| <i>Alpha-Glucosidase Inhibitors</i> | | |
| \$\$ Acarbose* | PRECOSE | QL = 90 tabs / month |
| Prior Authorization Required | | |
| <i>Incretin Mimetic</i> | | |
| \$\$\$\$ Exenatide | BYETTA | |
| \$\$\$\$ Liraglutide | VICTOZA | |
| Prior Authorization Required | | |
| <i>Diabetic Other</i> | | |
| \$ Metformin* | GLUCOPHAGE | |
| \$\$\$ Glucagon | GLUCAGON | |
| <u>THYROID</u> | | |
| <i>Thyroid Hormones</i> | | |
| \$ Levothyroxine* | LEVOXYL, SYNTHROID | |
| \$ Liothyronine* | CYTOMEL | |
| \$ Thyroid* | THYROID | |
| <i>Antithyroid Agents</i> | | |
| \$ Methimazole* | TAPAZOLE | |
| \$ Propylthiouracil* | PROPYLTHIURACIL | |
| <u>OXYTOCICS</u> | | |
| \$ Methylergonovine | METHERGINE | |

BioScrip/Jai Medical Systems Therapeutic Formulary

| <u>Generic Name</u> | <u>Brand Name</u> | <u>Annotation</u> |
|---|-------------------------|----------------------|
| <u>CALCIUM BLOCKERS</u> | | |
| \$\$\$ Amlodipine* | NORVASC | |
| \$\$\$ Amlodipine & Benazepril* | LOTREL | |
| \$\$\$ Diltiazem* | CARDIZEM/CD,DILACOR/XR | |
| \$\$ Felodipine* | PLENDIL | |
| \$\$\$ Nifedipine* | ADALAT CC, PROCARDIA XL | |
| \$\$ Verapamil* | CALAN, SR | |
| <u>ANTIARRHYTHMIC</u> | | |
| \$\$\$ Amiodarone* | CORDARONE | |
| \$ Disopyramide* | NORPACE, CR | |
| \$\$\$ Flecainide* | TAMBOCOR | |
| \$ Procainamide* | PRONESTYL, PROCANBID | |
| \$ Quinidine Sulfate* | QUINIDINE SULFATE | |
| \$\$\$\$ Mexiletine* | MEXILETINE | |
| \$\$\$\$ Propafenone* | RYTHMOL | |
| <u>ANTIHYPERTENSIVE</u> | | |
| <i>ACE Inhibitors</i> | | |
| \$ Captopril* | CAPOTEN | |
| \$\$ Benazepril* | LOTENSIN | |
| \$\$ Enalapril* | VASOTEC | |
| \$\$ Fosinopril* | MONOPRIL | |
| \$\$ Lisinopril* | ZESTRIL | |
| \$\$ Quinapril* | ACCUPRIL | |
| \$\$ Ramipril* | ALTACE | |
| <i>ACE II Inhibitors</i> | | |
| \$\$\$ Irbesartan* | AVAPRO | QL = 30 tabs / month |
| \$\$ Losartan potassium* | COZAAR | QL = 30 tabs / month |
| \$\$\$ Valsartan | DIOVAN | QL = 30 tabs / month |
| <i>Adrenolytics - Central</i> | | |
| \$ Clonidine* | CATAPRES | no patches |
| \$ Guanfacine* | TENEX | |
| \$ Methyldopa* | METHYLDOPA | |
| <i>Adrenolytics - Peripheral</i> | | |
| \$ Reserpine* | RESERPINE | |
| <i>Alpha Blockers</i> | | |
| \$\$ Doxazosin* | CARDURA | |
| \$ Prazosin* | MINIPRESS | |
| \$\$\$ Tamsulosin* | FLOMAX | |
| \$\$\$ Terazosin* | HYTRIN | |
| <i>Vasodilators</i> | | |
| \$ Hydralazine* | APRESOLINE | |
| \$ Minoxidil* | MINOXIDIL | |
| <i>Beta Blocker Combinations</i> | | |
| \$ Atenolol & Chlorthalidone* | TENORETIC | |
| \$\$\$ Metoprolol & HCTZ* | LOPRESSOR HCT | |
| \$ Propranolol & HCTZ* | INDERIDE | no LA |
| <i>ACE and ACE II Inhibitors & Diazides</i> | | |
| \$\$\$ Irbesartan & HCTZ | AVALIDE | QL = 30 tabs / month |
| \$\$ Lisinopril & HCTZ* | ZESTORETIC | |
| \$\$\$ Losartan potassium/HCTZ* | HYZAAR | QL = 30 tabs / month |
| \$\$\$ Valsartan & HCTZ | DIOVAN HCT | QL = 30 tabs / month |
| <i>Adrenolytics-Central & Thiazides</i> | | |
| \$ Methyldopa & HCTZ* | METHYLDOPA & HCTZ | |
| \$\$ Clonidine & Chlorthalidone* | CLOPRES | |

BioScrip/Jai Medical Systems Therapeutic Formulary

| <u>Generic Name</u> | <u>Brand Name</u> | <u>Annotation</u> |
|--|--|---|
| <i>Vasodilators & Thiazides</i> \$ Hydralazine & HCTZ* | HYDRALAZINE & HCTZ | |
| <u>DIURETICS</u> | | |
| <i>Carbonic Anhydrase Inhibitors</i> \$ Acetazolamide* \$\$\$ Methazolamide* | DIAMOX METHAZOLAMIDE | <i>no sequels</i> |
| <i>Loop Diuretics</i> \$ Furosemide* | LASIX | |
| <i>Potassium Sparing Diuretics</i> \$ Spironolactone* | ALDACTONE | |
| <i>Thiazides</i> \$ Chlorothiazide* \$ Chlorthalidone* \$ Hydrochlorothiazide* \$ Methyclothiazide* \$ Metolazone* \$ Indapamide* | DIURIL CHLORTHALIDONE HYDROCHLOROTHIAZIDE METHYCLOTHIAZIDE ZAROXOLYN INDAPAMIDE | |
| <i>Combination Diuretics</i> \$ Spironolactone & HCTZ* \$ Triamterene & HCTZ* | ALDACTAZIDE MAXZIDE | |
| <i>Osmotic Diuretics</i> \$ Glycerin Supp.* | GLYCERIN | <i>adult, infant, child</i> |
| <u>PRESSORS</u> | | |
| <i>Emergency Kits</i> \$\$ Epinephrine | EPI-PEN, EPI-PEN JR | |
| <u>ANTIHYPERLIPIDEMIC</u> | | |
| <i>Bile Sequestrants</i> \$\$\$ Cholestyramine* \$\$\$ Colestipol* | QUESTRAN, LIGHT COLESTID | <i>cans only</i> <i>cans only</i> |
| <i>Misc.</i> \$ Niacin* \$ Niacin CR \$\$\$ Fenofibrate* \$\$\$ Fenofibrate* \$\$ Gemfibrozil* \$\$\$\$ Omega-3-acid ethyl esters | NIACIN NIASPAN LOFIBRA TRICOR LOPID LOVAZA | <i>OTC (slow release)</i> <i>54mg and 160mg</i> <i>48mg and 145mg</i> |
| \$\$\$\$ Fenofibrate \$\$\$\$ Fenofibric acid \$\$\$\$ Fenofibrate micronized \$\$\$\$ Ezetimibe | LIPOFEN, TRIGLIDE TRILIPIX ANTARA ZETIA | |
| Prior Authorization Required | | |
| <i>HMG CoA Reductase Inhibitors</i> \$\$\$\$ Amlodipine & Atorvastatin \$\$\$\$ Atorvastatin* \$\$\$\$ Fluvastatin* \$\$ Lovastatin* \$\$\$\$ Niacin & Lovastatin \$ Pravastatin* \$ Simvastatin* | CADUET LIPITOR LESCOL MEVACOR ADVICOR PRAVACHOL ZOCOR | <i>QL = 30 tabs / month</i> <i>QL = 30 tabs / month</i> <i>QL = 30 tabs / month</i> <i>QL = 30 tabs / month</i> <i>QL = 30 tabs / month</i> |
| \$\$\$\$ Ezetimibe + Simvastatin \$\$\$\$ Rosuvastatin Calcium \$\$\$ Simvastatin* | VYTORIN CRESTOR ZOCOR | <i>80mg only / QL = 30 tabs / month</i> |
| Prior Authorization Required | | |

BioScrip/Jai Medical Systems Therapeutic Formulary

Generic Name

Brand Name

Annotation

VI. RESPIRATORY AGENTS

ANTI-HISTAMINES

Antihistamines - Ethanolamines
\$ Diphenhydramine*

BENADRYL

OTC product

Antihistamines - Non Sedating

\$\$ Loratadine*
\$\$ Loratadine / Pseudoephedrine*
\$\$ Cetirizine*
\$\$ Cetirizine tabs*
\$\$ Fexofenadine*
\$\$ Fexofenadine / Pseudoephedrine*

ALAVERT, CLARITIN
CLARITIN-D 12hr, 24hr
ZYRTEC
ZYRTEC
ALLEGRA OTC
ALLEGRA-D OTC 12hr, 24hr

OTC product
OTC product
chew tabs/liquid AL ≤ 18
30 or 60 per 30 days
30 or 60 per 30 days

Antihistamines - Phenothiazines

\$\$\$\$ Promethazine*

PHENERGAN

tabs only
AL ≥ 2 years

SYSTEMIC AND TOPICAL NASAL PRODUCTS

Nasal Antihistamines

| | |
|---------------------|---------|
| \$\$\$\$ Azelastine | ASTELIN |
|---------------------|---------|

Prior Authorization Required

Nasal Steroids

| | |
|-----------------------------|-------------|
| \$\$ Flunisolide* | NASALIDE |
| \$\$ Triamcinolone* | NASACORT AQ |
| \$\$\$ Fluticasone* | FLONASE |
| \$\$\$\$ Mometasone furoate | NASONEX |

Steroid Inhalants

| | |
|----------------------|---------------------|
| \$\$\$\$ Fluticasone | FLOVENT HFA |
| \$\$\$ Triamcinolone | AZMACORT |
| \$\$\$\$ Budesonide* | PULMICORT FLEXHALER |
| \$\$\$\$ Budesonide | PULMICORT RESPULES |

AL = 4 years and under
QL = 1 box / 30 days

| | |
|-------------------------------------|------|
| \$\$\$\$ Beclomethason Dipropionate | QVAR |
|-------------------------------------|------|

Mucolytics

| | |
|----------------------|----------|
| \$\$ Acetylcysteine* | MUCOMYST |
|----------------------|----------|

ANTI-ASTHMATIC

Anticholinergics

| | |
|--------------------|----------------|
| \$\$ Ipratropium* | ATROVENT/NASAL |
| \$\$\$ Ipratropium | ATROVENT HFA |
| \$\$\$ Tiotropium | SPIRIVA |

Anti-Inflammatory Agents

| | |
|------------------------------|-----------|
| \$\$\$ Cromolyn (inhalation) | INTAL |
| \$ Cromolyn (nasal)* | NASALCROM |

Beta Adrenergics

| | |
|-------------------|--------------------------------------|
| \$\$ Albuterol | PROVENTIL HFA, VENTOLIN HFA |
| \$\$ Albuterol* | ALBUTEROL NEBULIZER SOLUTION |
| | 0.5% (5mg/mL) and 0.083% (2.5mg/3mL) |
| \$\$\$ Pirbuterol | MAXAIR AUTOHALER |

| | |
|-------------------|-----------------|
| \$\$ Albuterol | PROAIR HFA |
| \$\$\$ Salmeterol | SEREVENT DISKUS |

Prior Authorization Required

Adrenergic Combinations

| | |
|--------------------------------|-------------------|
| \$\$\$\$ Albuterol-Ipratropium | COMBIVENT, DUONEB |
|--------------------------------|-------------------|

| | | |
|---------------------------------|---------------------|--------------|
| \$\$\$\$ Salmeterol-Fluticasone | ADVAIR / ADVAIR HFA | Step therapy |
| \$\$\$\$ Budesonide-Formoterol | SYMBICORT | Step therapy |

Prior Authorization Required

Sympathomimetic Agents

| | | |
|-------------------------|-----------------|-------------|
| \$ Pseudoephedrine HCL* | PSEUDOEPHEDRINE | OTC product |
|-------------------------|-----------------|-------------|

Mixed Adrenergics

| | |
|------------------|---------------------|
| \$\$ Epinephrine | EPI-PEN, EPI-PEN JR |
|------------------|---------------------|

BioScrip/Jai Medical Systems Therapeutic Formulary

| <u>Generic Name</u> | <u>Brand Name</u> | <u>Annotation</u> |
|---|---|-------------------|
| <i>Xanthines</i> | | |
| \$ Aminophylline* | AMINOPHYLLINE | |
| \$ Theophylline* | THEO-24, UNIPHYL | |
| <i>Leukotriene Receptor Antagonists</i> | | |
| \$\$\$ Montelukast Sodium* | SINGULAIR | |
| <u>COUGH/COLD/ALLERGY</u> | | |
| <i>Expectorants</i> | | |
| \$ Guaifenesin* | GUAIFENESIN | OTC product |
| \$ Guaifenesin/DM* | GUAIFENESIN DM | OTC product |
| <i>Cough/Cold/Allergy Combinations</i> | | |
| \$ Brompheniramine / Pseudoephedrine* | CVS COLD ALLERGY ELIXIR | |
| \$ Pseudoephedrine HCL soln* | PEDIACARE INFANT | |
| \$ Pseudoephedrine-Bromphen-DM* | CVS COLD ALLERGY DM ELIXIR | |
| \$ Pseudoephedrine-Chlorphen-DM* | CVS TRIACTING MULTI-SYMPTOM LIQUID | |
| \$ Pseudoephedrine-DM liquid* | CVS COUGH FORMULA D | |
| \$ Pseudoephedrine-DM soln* | CVS INFANT DECONGESTANT AND COUGH DROPS | |
| \$\$ Hydrocodone-GG* | HYCOTUSS | |
| \$\$ Pseudoephedrine-GG* | DURATUSS | |

VII. GASTROINTESTINAL AGENTS

LAXATIVES

| | | |
|--------------------------------|-----------|-------------|
| <i>Surfactant Laxatives</i> | | |
| \$ Docusate Sodium* | COLACE | OTC product |
| <i>Stimulant Laxatives</i> | | |
| \$ Bisacodyl* | DULCOLAX | OTC product |
| <i>Bulk Laxatives</i> | | |
| \$ Polycarbophil Calcium* | FIBERCON | OTC product |
| <i>Miscellaneous Laxatives</i> | | |
| \$ Glycerin* | GLYCERIN | OTC product |
| \$ Lactulose* | LACTULOSE | |
| \$ PEG-Electrolyte* | GOLYTELY | |

ANTI-DIARRHEALS

| | | |
|----------------------------------|--------------|--------------|
| <i>Antiperistaltic Agents</i> | | |
| \$ Diphenoxylate w/ Atropine* | LOMOTIL | |
| \$ Loperamide* | IMODIUM | OTC product |
| <i>Misc Antidiarrheal Agents</i> | | |
| \$ Bismuth Subsalicylate* | PEPTO-BISMOL | no tabs, OTC |
| \$\$\$\$ Octreotide Acetate* | SANDOSTATIN | |

| |
|-------------------------------------|
| Prior Authorization Required |
|-------------------------------------|

ANTACIDS

| | | |
|------------------------------------|--------------------|--------------|
| <i>Antacids - Aluminum Salts</i> | | |
| \$ Aluminum Hydroxide Gel* | ALUMINUM HYDROXIDE | OTC product |
| <i>Antacids - Calcium Salts</i> | | |
| \$ Calcium Carbonate* | OS-CAL | OTC product |
| <i>Antacid Combinations</i> | | |
| \$ Al Hydrox-Mag Carb* | MAALOX | no tabs, OTC |
| \$ Aluminum & Magnesium Hydroxide* | MYLANTA | no tabs, OTC |

BioScrip/Jai Medical Systems Therapeutic Formulary

| <u>Generic Name</u> | <u>Brand Name</u> | <u>Annotation</u> |
|--|--|---|
| <u>ULCER DRUGS</u> | | |
| <i>Belladonna Alkaloids</i> \$ Hyoscyamine Sulfate* | LEVSIN | |
| <i>Quaternary Anticholinergics</i> \$ Propantheline Bromide* | PRO-BANTHINE | |
| <i>Antispasmodics</i> \$ Dicyclomine* | BENTYL | |
| <i>H-2 Antagonists</i> \$ Famotidine* \$ Ranitidine* | PEPCID ZANTAC | <i>tabs only no caps</i> |
| <i>Proton Pump Inhibitors</i> \$\$ Omeprazole* \$\$ Lansoprazole* \$\$\$\$ Lansoprazole* \$\$\$ Pantoprazole* | PRIOSEC OTC PREVACID PREVACID PROTONIX | <i>OTC RX</i> |
| Prior Authorization Required | | |
| <i>Misc. Anti-Ulcer</i> \$\$ Sucralfate* \$\$\$\$ Sucralfate* | CARAFATE TABLETS CARAFATE SUSPENSION | |
| Prior Authorization Required | | |
| <u>ANTIEMETICS</u> | | |
| <i>Antiemetics - Anticholinergic</i> \$ Meclizine* \$\$ Prochlorperazine* | ANTIVERT PROCHLORPERAZINE | <i>no SR</i> |
| <i>5-HT3 Receptor Antagonists</i> Ondansetron* | ZOFRAN | <i>tablets only QL = 10 tabs per fill</i> |
| \$\$ Ondansetron* | ZOFRAN | <i>ODT: QL = 10 tabs per fill Suspension: QL = 50mls per fill</i> |
| Prior Authorization Required | | |
| <u>DIGESTIVE AIDS</u> | | |
| <i>Digestive Aids - Mixtures</i> \$\$\$\$ Amylase-Lipase-Protease Reg.Rls \$\$\$\$ Amylase-Lipase-Protease | VIOKACE CREON | |
| <u>MISC. GI</u> | | |
| <i>GI Stimulants</i> \$ Metoclopramide* | REGLAN | <i>no 5mg tabs</i> |
| <i>Inflammatory Bowel Agents</i> \$\$\$\$ Mesalamine \$\$\$\$ Mesalamine \$\$\$\$ Mesalamine \$ Sulfasalazine* | ASACOL PENTASA ROWASA AZULFIDINE | <i>400mg tabs no EN tabs</i> |
| VIII. GENITOURINARY | | |
| <u>URINARY ANTIINFECTIVES</u> | | |
| \$ Methenamine Mandelate* \$\$\$ Nitrofurantoin* \$\$ Nitrofurantoin Macrocrystals* \$ Trimethoprim* | MANDELAMINE FURADANTIN MACROBID PROLOPRIM | |
| <u>URINARY ANTISPASMODICS</u> | | |
| \$ Bethanechol* \$\$\$ Finasteride* \$\$\$ Flavoxate* \$ Hyoscyamine* \$ Oxybutynin* | URECHOLINE PROSCAR URISPAS LEVSINEX DITROPAN | |

BioScrip/Jai Medical Systems Therapeutic Formulary

| | | |
|---------------------|-------------------|-------------------|
| <u>Generic Name</u> | <u>Brand Name</u> | <u>Annotation</u> |
|---------------------|-------------------|-------------------|

VAGINAL PRODUCTS

Vaginal Antiinfectives

| | | |
|---------------------|------------------|--|
| \$\$ Clindamycin* | CLEOCIN | |
| \$ Nystatin* | NYSTATIN | |
| \$\$ Sulfanilamide | AVC | |
| \$\$ Metronidazole* | METROGEL-VAGINAL | |

| |
|-------------------------------------|
| Prior Authorization Required |
|-------------------------------------|

Imidazole-Related Antifungals

| | | |
|--------------------------|------------|-------------|
| \$ Butoconazole Nitrate* | GYNAZOLE-1 | OTC product |
| \$ Clotrimazole* | MYCELEX | OTC product |
| \$ Miconazole* | MONISTAT | OTC product |

Vaginal Antiinfective Combinations

| | | |
|---------------------------|-----------------------|--|
| \$ Triple Sulfas Vaginal* | TRIPLE SULFAS VAGINAL | |
|---------------------------|-----------------------|--|

MISCELLANEOUS GENITOURINARY PRODUCTS

Citrates

| | | |
|----------------------------------|--------|--|
| \$ Sodium Citrate & Citric Acid* | ORACIT | |
|----------------------------------|--------|--|

Urinary Analgesics

| | | |
|---------------------|----------|--|
| \$ Phenazopyridine* | PYRIDIUM | |
|---------------------|----------|--|

IX. CENTRAL NERVOUS SYSTEM DRUGS

ANTIPSYCHOTICS

Phenothiazines

| | | |
|------------------------|------------------|-------|
| \$\$ Prochlorperazine* | PROCHLORPERAZINE | no SR |
|------------------------|------------------|-------|

HYPNOTICS

Barbiturate Hypnotics

| | | |
|-------------------|---------------|--|
| \$ Butabarbital | BUTISOL | |
| \$ Mephobarbital | MEBARAL | |
| \$ Phenobarbital* | PHENOBARBITAL | |

Antihistamine Hypnotics

| | | |
|---------------------|----------|-------------|
| \$ Diphenhydramine* | BENADRYL | OTC product |
|---------------------|----------|-------------|

X. ANALGESICS & ANESTHETICS

ANALGESICS - NonNarcotic

Salicylates

| | | |
|------------------------|----------|--|
| \$ Aspirin zero order* | ZORPRIN | |
| \$\$ Salsalate* | AMIGESIC | |

Salicylate Combinations

| | | |
|--------------------------------|--------------------------|-------------|
| \$ Aspirin Enteric Coated* | ECOTRIN | OTC product |
| \$ Aspirin with Buffers* | ASPIRIN BUFFERED | OTC product |
| \$\$ Choline & Mag Salicylate* | CHOLINE & MAG SALICYLATE | |

Analgesics Other

| | | |
|-------------------|---------|-------------|
| \$ Acetaminophen* | TYLENOL | OTC product |
|-------------------|---------|-------------|

Analgesics - Sedatives

| | | |
|---------------------------------|----------|--|
| \$ APAP/Caffeine/Butalbital* | FIORICET | |
| \$ Aspirin/Caffeine/Butalbital* | FIORINAL | |

BioScrip/Jai Medical Systems Therapeutic Formulary

| <u>Generic Name</u> | <u>Brand Name</u> | <u>Annotation</u> |
|---|-------------------|---|
| <u>ANALGESICS - Narcotic</u> | | |
| <i>Narcotic Agonists</i> | | |
| \$ Codeine Phosphate* | CODEINE PHOSPHATE | |
| \$ Codeine Sulfate* | CODEINE SULFATE | |
| \$\$\$ Hydromorphone* | DILAUDID | |
| \$ Meperidine* | DEMEROL | |
| \$ Methadone* | METHADONE | |
| \$\$\$ Morphine Sulfate* | MSIR | |
| \$\$\$\$ Morphine Sulfate SR* | MS CONTIN | QL = 90 tabs/month for all strengths except 200mg: QL = 60 tabs/month |
| \$\$\$\$ Naltrexone* | REVIA | |
| \$\$\$ Oxycodone* | OXYIR | 5mg caps |
| \$\$\$ Oxycodone* | ROXICODONE | 5mg, 15mg, 30mg tabs and 20mg/mL oral soln |
| \$ Tramadol* | ULTRAM | QL = 240 tabs/30 days |
| \$\$\$ Tramadol/APAP* | ULTRACET | QL = 240 tabs/30 days |
| \$\$\$ Fentanyl* | DURAGESIC | QL = 10 patches/30days |
| \$\$\$\$ Oxycodone CR* | OXYCONTIN | QL = 60 tabs/30days |
| Prior Authorization Required | | |
| <i>Narcotic Agonist-Antagonist</i> | | |
| \$\$\$\$ Buprenorphine HCL-Naloxone HCL | SUBOXONE | |
| <i>Opiate Partial Agonist</i> | | |
| \$\$\$\$ Buprenorphine HCL* | SUBUTEX | QL = 1 fill / 6 months |
| <i>Narcotic Combinations</i> | | |
| \$ Oxycodone w/ Acetaminophen* | PERCOCET | QL = 120 5/500 tabs and caps, 5/325 tabs and soln |
| \$ Oxycodone w/ Aspirin* | PERCODAN | |
| <i>Codeine Combinations</i> | | |
| \$ Acetaminophen w/ Codeine* | TYLENOL / CODEINE | |
| \$ Aspirin w/ Codeine* | ASPIRIN / CODEINE | |
| <i>Hydrocodone Combinations</i> | | |
| \$\$ Acetaminophen w/ Hydrocodone* | VICODIN, LORTAB | QL = 180 tabs/month 5/500 tabs and 7.5/500mg elixir only |
| <i>Propoxyphene Combinations</i> | | |
| \$ Propoxyphene w/ APAP* | DARVOCET N-100 | 100mg tabs |
| <u>ANTI-RHEUMATIC</u> | | |
| <i>NSAID's</i> | | |
| \$\$ Diclofenac* | VOLTAREN | |
| \$\$ Etodolac* | ETODOLAC | |
| \$\$ Fenoprofen* | NALFON | |
| \$\$\$ Flurbiprofen* | ANSAID | |
| \$ Ibuprofen* | MOTRIN | |
| \$ Indomethacin* | INDOCIN | no SR or supp. |
| \$ Meloxicam* | MOBIC | |
| \$ Naproxen* | NAPROSYN | no EC |
| \$ Naproxen Sodium* | ANAPROX | |
| \$ Piroxicam* | FELDENE | |
| \$\$ Sulindac* | CLINORIL | |
| <i>COX-2 Inhibitor</i> | | |
| \$\$\$\$ Celecoxib | CELEBREX | |
| Prior Authorization Required | | |
| <i>Anti-Rheumatic Antimetabolite</i> | | |
| \$\$\$\$ Methotrexate* | RHEUMATREX | |
| <u>GOUT</u> | | |
| \$ Allopurinol* | ZYLOPRIM | |
| \$\$\$\$ Colchicine | COLCRYS | |
| <i>Uricosurics</i> | | |
| \$ Probenecid* | PROBENECID | |

BioScrip/Jai Medical Systems Therapeutic Formulary

| | | |
|---------------------|-------------------|-------------------|
| <u>Generic Name</u> | <u>Brand Name</u> | <u>Annotation</u> |
|---------------------|-------------------|-------------------|

LOCAL ANESTHETICS

| | | |
|-------------------------------------|------------------|------------------------|
| \$ Lidocaine* | LIDOCAINE | 2% gel only |
| \$\$\$\$\$ Lidocaine | LIDODERM PATCHES | QL = 90 patches/30days |
| Prior Authorization Required | | |

MIGRAINE PRODUCTS

| | | |
|-------------------------------------|-----------|---------------------------|
| \$\$\$ Ergoloid mesylates* | HYDERGINE | |
| \$\$\$ Ergotamine tartrate | ERGOMAR | |
| \$\$\$ Sumatriptan tablets | IMITREX | QL = 9 tabs/30 days |
| \$\$\$ Sumatriptan Injection | IMITREX | QL = 2 injections/30 days |
| \$\$\$ Sumatriptan-naproxen | TREXIMET | (no nasal spray) |
| \$\$\$\$\$ Rizatriptan tablets | MAXALT | QL = 9 tabs / 30 days |
| \$\$\$ Zolmitriptan tablets | ZOMIG | QL = 6 tabs / 30 days |
| Prior Authorization Required | | |
| <i>Migraine Combinations</i> | | |
| \$\$ Ergotamine w/ Caffeine | CAFERGOT | |

XI. NEUROMUSCULAR AGENTS

ANTICONVULSANT

| | | |
|--------------------------------------|----------|--|
| <i>Hydantoins</i> | | |
| \$ Phenytoin* | DILANTIN | |
| <i>Succinimides</i> | | |
| \$\$ Ethosuximide* | ZARONTIN | |
| <i>Miscellaneous Anticonvulsants</i> | | |
| \$\$\$ Primidone* | MYSOLINE | |

ANTIPARKINSONIAN

| | | |
|-------------------------------------|-------------|-------------------|
| <i>COMT Inhibitors</i> | | |
| \$\$\$ Entacapone | COMTAN | |
| Prior Authorization Required | | |
| <i>Dopaminergic</i> | | |
| \$ Amantadine* | SYMMETREL | |
| \$\$\$ Bromocriptine* | PARLODEL | no postpartum use |
| \$\$ Ropinirole* | REQUIP | |
| Prior Authorization Required | | |
| <i>Levodopa Combinations</i> | | |
| \$\$\$ Carbidopa-Levodopa* | SINEMET, CR | no 100-25 CR |
| <i>Monoamine Oxidase Inhibitor</i> | | |
| \$\$\$\$ Selegiline* | ELDEPRYL | |

MUSCULOSKELETAL THERAPY AGENTS

| | | |
|-------------------------------------|---------------------|--|
| <i>Central Muscle Relaxants</i> | | |
| \$\$ Baclofen* | BACLOFEN | |
| \$ Cyclobenzaprine* | FLEXERIL | |
| \$ Methocarbamol* | ROBAXIN | |
| <i>Direct Muscle Relaxants</i> | | |
| \$\$\$\$ Dantrolene* | DANTRIUIM | |
| Prior Authorization Required | | |
| <i>Fibromyalgia</i> | | |
| \$\$\$\$\$ Milnacipran | SAVELLA | |
| Prior Authorization Required | | |
| <i>Muscle Relaxant Combinations</i> | | |
| \$ Methocarbamol w/ Aspirin* | METHOCARBAMOL w/ASA | |

BioScrip/Jai Medical Systems Therapeutic Formulary

| | | |
|---------------------|-------------------|-------------------|
| <u>Generic Name</u> | <u>Brand Name</u> | <u>Annotation</u> |
|---------------------|-------------------|-------------------|

ANTIMYASTHENIC AGENTS

| | |
|--|----------|
| <i>Antimyasthenic Agents</i> \$\$\$\$ Pyridostigmine* | MESTINON |
|--|----------|

Benzothiazoles

| | |
|-------------------------------------|---------|
| \$\$\$\$\$ Riluzole | RILUTEK |
| Prior Authorization Required | |

XII. NUTRITIONAL PRODUCTS

VITAMINS

| | | |
|--|----------------------|-----------------------|
| <i>Water Soluble Vitamins</i> \$ Niacin* | NIACIN | |
| <i>Oil Soluble Vitamins</i> \$ Vitamin A* | VITAMIN A | |
| <i>Vitamin D</i> \$\$ Calcitriol* \$\$ Ergocalciferol* | ROCALTROL DRISDOL | |
| <i>Vitamin K</i> \$\$ Mephyton | VITAMIN K | QL = 5 tabs / 30 days |

MULTIVITAMINS

| | | |
|--|-------------------------|-----------------------|
| \$ Folic Acid & Vitamin B Complex* | NEPHROCAPS | |
| \$ Multiple Vitamin* | ONE-A-DAY | OTC product |
| \$ Multiple Vitamin w/ Minerals* | BEROCCA PLUS | |
| \$ Pediatric Vitamins* | CHILDS COMPLETE | OTC product |
| \$ Pediatric Multivitamins w/Fluoride* | POLY-VI-FLOR | 6mos to 16 years only |
| \$ Pediatric Multivitamins w/Iron* | ONE-A-DAY KIDS COMPLETE | |
| \$ Prenatal MV & Min w/FE-FA* | PRENATAL-1 | |
| \$ Prenatal Vitamins* | MATERNA | |

CITRATES

| | |
|----------------------------------|--------|
| \$ Sodium Citrate & Citric Acid* | ORACIT |
|----------------------------------|--------|

MINERALS & ELECTROLYTES

| | | |
|--|------------------|--------------------------|
| <i>Calcium</i> \$ Calcium Acetate* \$ Calcium Carbonate* | PHOSLO OS-CAL | caps only OTC product |
|--|------------------|--------------------------|

| | |
|--|--------|
| <i>Fluoride</i> \$ Sodium Fluoride* | LURIDE |
|--|--------|

| | |
|--|--|
| <i>Potassium</i> \$ Potassium Chloride Capsule* \$ Potassium Chloride Liquid* \$ Potassium Chloride Tablet* | MICRO-K POTASSIUM CHLORIDE LIQUID KLOR-CON |
|--|--|

| | | |
|--|-----------|-------------|
| <i>Electrolyte Mixtures</i> \$ Oral Electrolytes* | PEDIALYTE | OTC product |
|--|-----------|-------------|

DIETARY PRODUCTS

| | | |
|--|--------------------------|----------------------------|
| \$\$ Infant Foods \$\$ Phenyl-Free* | LOFENALAC PHENYL-FREE | OTC product OTC product |
|--|--------------------------|----------------------------|

MISCELLANEOUS NUTRITIONAL PRODUCTS

| | |
|--|--------------------------------------|
| \$\$\$\$ Nutritional Supplements | ENSURE, PEDIASURE, BOOST, VIVONEX |
| Prior Authorization Required (Nutritional Supplements are not limited to this list) | |

BioScrip/Jai Medical Systems Therapeutic Formulary

Generic Name

Brand Name

Annotation

XIII. HEMATOLOGICAL AGENTS

HEMATOPOIETIC AGENTS

Cobalamines

| | | |
|-------------------------------------|------------------|--|
| \$ Folic Acid* | FOLIC ACID | |
| \$\$\$ Leucovorin Calcium* | LEUCOVORIN | |
| \$ Cyanocobalamin* | VITAMIN B-12 | |
| \$ Hydroxocobalamin* | HYDROXOCOBALAMIN | |
| Prior Authorization Required | | |

Iron

| | | |
|-----------------------|--------|-------------|
| \$ Ferrous Gluconate* | FERGON | OTC product |
| \$ Ferrous Sulfate* | FEOSOL | OTC product |

Hematopoietic Growth Factors

| | | |
|-------------------------------------|---------|----------------------|
| \$\$\$\$ Darbepoetin | ARANESP | 4 injections / month |
| Prior Authorization Required | | |

Erythropoietins

| | | |
|-------------------------------------|-----------------|---|
| \$\$\$\$\$ Epoetin Alfa | EPOGEN, PROCRIT | 2,000U, 3,000U, 4,000U, 10,000 - QL = 12 injections / month |
| Prior Authorization Required | | 20,000U, 40,000U - QL = 4 injections / month |

Leukocytes

| | | |
|-------------------------------------|----------|-------------------------------|
| \$\$\$\$\$ Filgrastim | NEUPOGEN | QL = 30 injections / month |
| Prior Authorization Required | | |

ANTICOAGULANTS

Coumarin Anticoagulants

| | | |
|-----------------------|----------|--|
| \$\$ Warfarin Sodium* | COUMADIN | |
|-----------------------|----------|--|

Heparin Agents

| | | |
|------------------------|---------|--|
| \$\$\$\$\$ Enoxaparin* | LOVENOX | |
|------------------------|---------|--|

Thrombin Inhibitors

| | | |
|-------------------------------------|---------|--|
| \$\$\$\$\$ Dabigatran | PRADAXA | |
| Prior Authorization Required | | |

HEMOSTATICS

Hemostatics - Topical

| | | |
|-------------------------------------|----------|--|
| \$\$\$\$ Thrombin | THROMBIN | |
| Prior Authorization Required | | |

MISC. HEMATOLOGICAL

Antihemophilic Products

| | | |
|--|---------------|--|
| \$\$\$\$\$ Antihemophilic Factor (Human) | ALPHANATE | |
| \$\$\$\$\$ Antihemophilic Factor (Recombinate) | RECOMBINATE | |
| \$\$\$\$\$ Antiinhibitor Coagulant Complex | FEIBA VH | |
| \$\$\$\$\$ Antithrombin III (Human) | THROMBATE III | |
| Prior Authorization Required | | |

Platelet Aggregation Inhibitors

| | | |
|---------------------|--------|--|
| \$\$\$ Clopidogrel* | PLAVIX | |
|---------------------|--------|--|

Hematorheological

| | | |
|-------------------------------------|---------|--|
| \$\$ Pentoxifylline* | TRENTAL | |
| Prior Authorization Required | | |

BioScrip/Jai Medical Systems Therapeutic Formulary

Generic Name

Brand Name

Annotation

XIV. BEHAVIORAL HEALTH AGENTS

MISCELLANEOUS

Smoking Deterrents
 \$\$\$ Nicotine*

HABITROL, NICOTROL, PROSTEP
 NICODERM, NICODERM CO

\$\$\$\$ Varenicline Tartrate
 CHANTIX
Prior Authorization Required

Reversible Acetylcholinesterase inhibitor

\$\$\$\$ Donepezil* ARICEPT
 \$\$\$\$ Galantamine* RAZADYNE / RAZADYNE ER
 \$\$\$\$ Rivastigmine* EXELON
Prior Authorization Required

Miscellaneous

\$\$\$ Disulfiram* ANTABUSE
 \$\$\$\$ Acamprosate CAMPRAL
 \$\$\$\$\$ Clonidine KAPVAY *Please refer to Introduction page I-5*
 \$\$\$\$\$ Guanfacine INTUNIV *Please refer to Introduction page I-5*
 \$\$\$\$ Memantine NAMENDA
Prior Authorization Required

ANTICONVULSANT

Misc. Anticonvulsants
 \$\$\$ Primidone*

MYSOLINE

XV. TOPICAL AGENTS

OPHTHALMIC

Antibiotics

\$\$\$ Bacitracin* AK-TRACIN
 \$\$\$ Ciprofloxacin* CILOXAN
 \$ Erythromycin* ROMYCIN
 \$ Gentamicin Sulfate* GENTAK
 \$ Polymyxin B-Trimethoprim* POLYTRIM
 \$\$\$ Moxifloxacin Hydrochloride VIGAMOX *AL = 18 years*
 \$\$\$ Gatifloxacin ZYMAXID
Prior Authorization Required

Anti Allergic

\$\$\$ Lodoxamine ALOMIDE *QL = 20 mls / 30 days*
 \$\$\$\$ Olopatadine PATANOL *QL = 20 mls / 30 days*

Sulfonamides

\$ Sodium Sulfacetamide* BLEPH-10

Antivirals

\$\$\$ Trifluridine* VIROPTIC
 \$ Vidarabine VIRA-A

Antiffective Combinations

\$ Bacitracin-Polymyxin B* POLYSPORIN
 \$ Neomycin-Bac Zn-Polymyxin* NEOMYCIN-BAC ZN-POLYMXIN
 \$ Neomycin-Polymy-Gramicidin* NEOSPORIN

Beta-Blockers

\$\$\$\$ Betaxolol* BETOPTIC, BETOPTIC S
 \$ Timolol* BETIMOL, TIMOPTIC *no XE*

Steroids

\$\$ Dexamethasone* DEXAMETHASONE
 \$\$ Prednisolone Acetate* PRED FORTE, MILD

Steroid Combinations

\$ Bacitracin-Polymyxin-Neomycin-HC* BACITRACIN-POLYMXIN-NEOMYCIN-HC
 \$ Neomycin-Polymyxin-Dexamethasone* MAXITROL
 \$\$\$ Neomycin-Polymyxin-HC* CORTISPORIN
 \$\$\$ Sulfacetamide Sod-Prednisolone* BLEPHAMIDE

BioScrip/Jai Medical Systems Therapeutic Formulary

| <u>Generic Name</u> | <u>Brand Name</u> | <u>Annotation</u> |
|---|---|------------------------------------|
| <i>Cycloplegics</i> \$ Atropine Sulfate* | ISOPTO ATROPINE | |
| <i>Decongestants</i> \$ Naphazoline* \$\$ Phenylephrine* | NAPHCON MYDRIN | |
| <i>Ophthalmic NSAID's</i> \$\$ Flurbiprofen* | OCUFEN | |
| <i>Miotics - Direct Acting</i> \$ Pilocarpine* | ISOPTO-CARPINE | <i>no Ocuser</i> |
| <i>Adrenergic Agents</i> \$\$ Dipivefrin* | PROPINE | |
| <i>Prostaglandins</i> \$\$\$ Latanoprost* | XALATAN | |
| <i>Carbonic Anhydrase Inhibitors</i> \$\$ Dorzolamide* | TRUSOPT | |
| <u>OTIC</u> | | |
| <i>Steroids</i> \$ Hydrocortisone w/Acetic Acid* | ACETASOL HC | <i>QL = 20 mls / 30 days</i> |
| <i>Antibiotics & Steroid-Antibiotic Combinations</i> \$ Neomycin-Polymyxin-HC* | CORTISPORIN | <i>QL = 20 mls / 30 days</i> |
| <i>Antibiotics</i> \$\$\$ Ofloxacin* | FLOXIN | <i>QL = 20 mls / 30 days</i> |
| <i>Anti Infective</i> \$ Carbamide Peroxide* | DEBROX | |
| <i>Analgesic Combinations</i> \$ Benzocaine & Antipyrine* | A/B OTIC | |
| <u>MOUTH & THROAT (Local)</u> | | |
| <i>Antiinfectives - Throat</i> \$\$\$ Clotrimazole* \$ Nystatin* | MYCELEX TROCHE NYSTATIN | |
| <u>ANORECTAL</u> | | |
| <i>Rectal Steroids</i> \$ Hydrocortisone* \$\$ Hydrocortisone* | ANUSOL-HC PROCTOCREAM | <i>2.5% cream 2.5% cream</i> |
| <u>DERMATOLOGICAL</u> | | |
| <i>Antibiotics - Topical</i> \$\$ Bacitracin* \$ Gentamicin Sulfate* \$\$\$ Metronidazole \$\$\$ Mupirocin* \$ Neomycin Sulfate* | BACITRACIN GENTAMICIN METROGEL BACTROBAN NEOMYCIN | <i>OTC product</i> |
| <i>Antibiotic Mixtures Topical</i> \$ Neomycin-Bacitracin-Polymyxin* | NEOSPORIN | <i>OTC product</i> |
| <i>Antibiotic Steroid Combinations</i> \$\$ Neomycin-Polymyxin-HC* | CORTISPORIN | |
| <i>Imidazole-Related Antifungals (Topical)</i> \$\$ Clotrimazole* \$ Miconazole* | LOTRIMIN MONISTAT | <i>OTC product OTC product</i> |
| <i>Antifungals</i> \$ Nystatin* | NYSTATIN | <i>no powder</i> |
| <i>Antifungals - Topical Combinations</i> \$\$ Nystatin-Triamcinolone* | NYSTATIN-TRIAMCINOLONE | |

BioScrip/Jai Medical Systems Therapeutic Formulary

| <u>Generic Name</u> | <u>Brand Name</u> | <u>Annotation</u> |
|--|----------------------------|------------------------------|
| <i>Antipsoriatics</i> | | |
| \$\$\$\$ Calcipotriene* | DOVONEX | |
| <i>Antiseborrheic Products</i> | | |
| \$ Sulfacetamide Sodium* | SULFACETAMIDE SODIUM | |
| <i>Burn Products</i> | | |
| \$ Silver Sulfadiazine* | SILVADENE | |
| <i>Tar Products</i> | | |
| \$ Coal Tar* | COAL TAR SHAMPOO | 1% only |
| <i>Enzymes - Topical</i> | | |
| \$\$\$ Collagenase | SANTYL | |
| <i>Keratolytics/Antimitotics</i> | | |
| \$\$\$\$ Podofilox | CONDYLOX | |
| \$\$\$\$\$ Urea 35% | KERALAC | |
| \$\$\$\$\$ Urea 50% | KERALAC NAILSTIK | |
| <i>Local Anesthetics - Topical</i> | | |
| \$ Lidocaine viscous* | XYLOCAINE VISCOUS | |
| <i>Scabicides & Pediculocides</i> | | |
| \$ Lindane* | LINDANE | |
| \$\$ Permethrin* | ELIMITE | OTC product |
| \$\$ Permethrin* | NIX | |
| <i>Misc. Topical</i> | | |
| \$\$ Ammonium Lactate* | LAC-HYDRIN | cream & lotion |
| \$\$\$ Fluorouracil* | EFUDEX | 2% and 5% cream only |
| \$\$\$ Pimecrolimus | ELIDEL | |
| Prior Authorization Required | | |
| <i>Antiviral Topical</i> | | |
| \$\$\$\$ Acyclovir | ZOVIRAX | |
| Prior Authorization Required | | |
| <i>Corticosteroids - Topical</i> | | |
| \$ Betamethasone Dipropionate* | BETAMETHASONE DIPROPIONATE | |
| \$ Betamethasone Valerate* | BETAMETHASONE VALERATE | |
| \$ Clobetasol Propionate* | TEMOVATE | |
| \$ Desonide* | DESOWEN | |
| \$ Fluocinonide* | LIDEX | |
| \$ Fluocinonide Acetonide* | SYNALAR | |
| \$ Hydrocortisone* | HYTONE | OTC product |
| \$ Triamcinolone Acetonide* | KENALOG | |
| \$ Triamcinolone Acetonide in Orabase* | TRIAM. ACET. IN ORABASE | |
| <i>Acne Products</i> | | |
| \$ Benzoyl Peroxide* | BENZAC W | |
| \$\$\$ Tretinoin* | RETIN-A | Ages 0-21 only / no Micro |
| <i>Acne Antibiotics</i> | | |
| \$\$ Clindamycin Phosphate* | CLEOCIN | |
| \$\$ Erythromycin Gel* | ERYGEL | |

XVI. MISCELLANEOUS PRODUCTS

ANTIDOTES

| | | |
|------------|--------|-------------|
| \$ Ipecac* | IPECAC | OTC product |
|------------|--------|-------------|

DIAGNOSTIC PRODUCTS

| | | |
|----------------------------|-----------|--|
| <i>Diagnostic Reagents</i> | | |
| \$ Acetone Tablets | ACETEST | |
| \$ Acetone Test* | KETOSTIX | |
| \$ Glucose Urine Test* | CLINITEST | |
| \$\$ Glucose Blood* | GLUCOFILM | |

BioScrip/Jai Medical Systems Therapeutic Formulary

Generic Name

Brand Name

Annotation

MEDICAL DEVICES

Parenteral Therapy Supplies

| | | |
|-----------------------------------|---------------------|--|
| \$ Disposable Needles & Syringes* | B-D INSULIN SYRINGE | |
| \$ Insulin Pen Needles | Insulin Pen Needles | |

Diabetic Supplies

| | | |
|------------------------------------|----------------------|---|
| \$ Blood Glucose Monitoring Tests* | GLUCOMETER | <i>Only Bayer Contour Ascensia Glucometer</i> |
| \$ Calibration Solution* | CALIBRATION SOLUTION | |
| \$ Lancet Device | HYPOLET | |
| \$ Lancets* | LANCETS | |

Misc. Devices

| | | |
|-------------------|--------------|--|
| \$ Alcohol Swabs* | ALCOHOL PADS | |
|-------------------|--------------|--|

CONTRACEPTIVES

\$ Condoms

ASSORTED CLASSES

Chelating Agents

| | | |
|-----------------------|-----------|--|
| \$\$\$\$ Pencillamine | CUPRIMINE | |
| \$\$\$\$ Succimer | CHEMET | |

Prior Authorization Required

Immunosuppressive Agents

| | | |
|----------------------------------|----------|--|
| \$\$\$\$ Cyclosporine Microsize* | NEORAL | |
| \$\$\$\$ Sirolimus | RAPAMUNE | |
| \$\$\$\$ Tacrolimus* | PROGRAF | |

Inosine Monophosphate Dehydrogenase Inhibitors

| | | |
|---------------------------------|----------|--|
| \$\$\$\$ Mycophenolate Mofetil* | CELLCEPT | |
| \$\$\$\$ Mycophenolate Sodium | MYFORTIC | |

Multiple Sclerosis - Adjuvants

| | | |
|------------------------|--------|-------------------------------|
| \$\$\$\$ Dalfampridine | AMPYRA | <i>QL = 60 tabs / 30 days</i> |
|------------------------|--------|-------------------------------|

Prior Authorization Required

Purine Analogs

| | | |
|----------------------|--------|--|
| \$\$\$ Azathioprine* | IMURAN | |
|----------------------|--------|--|

K Removing Resin

| | | |
|--|------------|--|
| \$\$\$\$ Sodium Polystyrene Sulfonate* | KAYEXALATE | |
|--|------------|--|

Rheumatology Biologics

| | | |
|---------------------|--------|--|
| \$\$\$\$ Adalimumab | HUMIRA | |
| \$\$\$\$ Etanercept | ENBREL | |

Prior Authorization Required

Prior Authorization Guidelines

Prior Authorization Guidelines

GENERIC: ACAMPROSATE

BRAND: CAMPRAL[®]

INDICATION:

- (1) Maintenance of abstinence for alcohol-dependent patients who are abstinent at treatment initiation.

Criteria:

- (a) Patient must be abstinent at treatment initiation; **and**
- (b) Treatment must be part of a comprehensive management program that includes psychosocial support; **and**
- (c) Patient must be opiate dependent.

GENERIC: ACARBOSE

BRAND: PRECOSE[®]

INDICATION:

- (1) Type 2 diabetes mellitus

Criteria:

- (a) Failure of maximal doses of *one* oral sulfonylurea (e.g., glyburide 20mg daily or equivalent). Failure is defined as Hemoglobin A1c > 7.0.

GENERIC: ACYCLOVIR TOPICAL OINTMENT

BRAND: ZOVIRAX[®] 5%

INDICATIONS:

- (1) Herpes genitalis
- (2) Oral herpes infection

Criteria:

- (a) Herpes genitalis – for initial episode only; **or**
- (b) Oral herpes infection – for immunocompromised patients *only*.

GENERIC: ADALIMUMAB

BRAND: HUMIRA[®]

INDICATIONS:

- (1) Moderate to severely active rheumatoid arthritis
- (2) Psoriatic arthritis
- (3) Ankylosing spondylitis
- (4) Moderate to severe active Crohn's disease

Prior Authorization Guidelines

Criteria:

- (a) The patient had a NEGATIVE tuberculin skin test, or if positive, has received treatment for latent TB prior to Humira therapy; **and**
- (b) The patient does not have a clinically important active infection

Additional Criteria for RA:

- (a) The patient has failed or is intolerant to one formulary NSAID **and**
- (b) The patient has failed or is intolerant to one formulary DMARD

Additional Criteria for Crohn's:

- (a) The patient has failed or is intolerant to infliximab; **or**
- (b) The patient has failed or is intolerant to mesalamine or sulfasalazine; **and**
- (c) The patient has failed or is intolerant to corticosteroids; **and**
- (d) The patient has failed or is intolerant to an immunomodulator (e.g., methotrexate, 6-mercaptopurine or azathioprine)

GENERIC: ANTIHEMOPHILIC FACTORS

BRAND: ALPHANATE[®], FEIBA VH[®], RECOMBINATE[®], THROMBATE III[®]

INDICATION:

- (1) Hemophilia A

Criteria:

- (a) Diagnosis of Hemophilia A

GENERIC: AZELASTINE

BRAND: ASTELIN[®]

INDICATIONS:

- (1) Allergic conjunctivitis
- (2) Perennial allergic rhinitis
- (3) Seasonal allergic rhinitis

Criteria:

- (a) Patient is ≥ 5 years of age with one of the above diagnoses; **and**
- (b) Failure of at least one formulary nasal steroid after a period of at least two months on the maximum dose appropriate and tolerated by the patient

Prior Authorization Guidelines

GENERIC: BOCEPREVIR

BRAND: VICTRELIS[®]

INDICATION:

- (1) Treatment of chronic hepatitis C genotype 1 used in combination with peginterferon alfa and ribavirin in patients with compensated liver disease.

Criteria:

- (a) Diagnosis of chronic hepatitis C genotype 1; **and**
- (b) Diagnosis of compensated liver disease; **and**
- (c) No previous treatment (full or partial course) of Incivek or Victrelis; **and**
- (d) Patient has been counseled on the importance of medication adherence and is willing to adhere to the regimen for the full course of therapy; **and**
- (e) The patient must have completed 4 weeks of peginterferon and ribavirin therapy (treatment weeks 1 through 4); **and**
- (f) HCV-RNA levels must be drawn at treatment weeks 8, 12, and 24 (Victrelis week 4, 8, and 20); **and**
- (g) Females of child bearing potential must meet the following additional parameters:
 - a. A recent negative pregnancy test; **and**
 - b. Been counseled on the teratogenic effects of triple therapy; **and**
 - c. Is willing to practice contraception during and for 6 months after completion of therapy

GENERIC: BUDESONIDE/FORMOTEROL

BRAND: SYMBICORT[®]

INDICATIONS:

- (1) Maintenance treatment of asthma in patients 12 years of age and older

Criteria:

- (a) Currently on, but not adequately controlled by an inhaled corticosteroid; **or**

Prior Authorization Guidelines

- (b) Maintenance treatment of airflow obstruction in patients with chronic bronchitis and emphysema
- (c) Patients must be reevaluated after 6 months

**For members currently with an approved prior authorization for Symbicort, claims will process as long as the member has filled Symbicort within the last 3 months. No yearly renewal will be needed for compliant members. Prior authorization will be required for members new to the plan, new to Symbicort therapy, or with no claim history of Symbicort within the last 3 months.*

GENERIC: CALCITONIN-SALMON

BRAND: MIACALCIN[®]

INDICATIONS:

- (1) Mild to moderate Paget's disease of bone
- (2) Osteoporosis

Criteria:

- (a) Failure, contraindication or intolerance to adequate trial of oral bisphosphonate; **and**
- (b) One of the following:
 - (1) Bone density measurement ≥ 2.5 standard deviations below the mean for normal, young adults of same gender (T-score ≤ -2.5); **or**
 - (2) History of an osteoporotic vertebral fracture; **or**
 - (3) Postmenopausal woman with low bone mineral density defined by T-score between -2.0 and -2.5 AND one of the following risk factors for fracture:
 - (a) Thinness or low body mass index defined by weight < 127 lb (57.7 kg) or BMI < 21 kg/m²
 - (b) History of fragility fracture since menopause
 - (c) History of hip fracture in a parent
 - (4) Diagnosis of Paget's disease of bone
- (c) Patients receiving glucocorticoids in daily dosages of ≥ 7.5 mg prednisone daily (see table) AND who have bone density measurement > 1 standard deviations below the mean for normal, young adults of same gender (T-score < -1.0)

Prior Authorization Guidelines

| Glucocorticoid Potency Equivalencies | | | |
|---|---|--|---|
| Glucocorticoid | Approximate equivalent dose (mg) | Relative anti-inflammatory (glucocorticoid) potency | Relative mineralocorticoid potency |
| <i>Short-acting</i> | | | |
| Cortisone | 25 | 0.8 | 2 |
| Hydrocortisone | 20 | 1 | 2 |
| <i>Intermediate-acting</i> | | | |
| Prednisone | 5 | 4 | 1 |
| Prednisolone | 5 | 4 | 1 |
| Triamcinolone | 4 | 5 | 0 |
| Methylprednisolone | 4 | 5 | 0 |
| <i>Long-acting</i> | | | |
| Dexamethasone | 0.75 | 20-30 | 0 |
| Betamethasone | 0.6-0.75 | 20-30 | 0 |

Table adapted from Facts and Comparisons® 1999:122

** For injectable medications administered by a healthcare professional, please refer to the “Specialty Medication Guidelines” in the beginning of this formulary.*

** If documentation of osteoporosis is available, please submit with PA request.*

GENERIC: CEFDINIR SUSPENSION

BRAND: OMNICEF[®]

INDICATIONS:

- (1) CAP
- (2) Acute exacerbations of chronic bronchitis
- (3) Acute maxillary sinusitis
- (4) Pharyngitis / Tonsillitis
- (5) Uncomplicated skin and skin structure infections
- (6) Acute bacterial otitis media – pediatrics only

Criteria:

- (a) Recent failure (within 30 days) of at least one standard first-line formulary antibiotic in absence of culture; **or**
- (b) Documentation of cultured organism with sensitivity to only cefdinir, other third generation cephalosporin OR contraindications to all other sensitive antibiotics.

Prior Authorization Guidelines

GENERIC: CELECOXIB

BRAND: CELEBREX[®]

INDICATIONS:

- (1) Relief of signs and symptoms of rheumatoid arthritis (RA) in adults
- (2) Relief of signs and symptoms of osteoarthritis (OA)
- (3) Relief of signs and symptoms of ankylosing spondylitis
- (4) Management of acute pain in adults
- (5) Treatment of primary dysmenorrhea
- (6) To reduce the number of adenomatous polyps in familial adenomatous polyposis, as an adjunct to usual care

Criteria:

- (a) Failure, intolerance, or contraindication to at least 2 formulary NSAIDs; **and**
- (b) One of the following:
 - (1) Age greater than 65; **or**
 - (2) Concomitant use of warfarin or other antiplatelet therapy; **or**
 - (3) Concomitant use of chronic systemic corticosteroid therapy; **or**
 - (4) Documented history of ulcer disease or GI bleed; **or**
 - (5) Documented history of significant GI disease requiring therapy with an H2 antagonist or proton pump inhibitor; **or**
 - (6) Documented history of nonselective NSAID-induced GI adverse effects; **and**
- (c) For OA, therapeutic failure (≥ 21 day trial), intolerance of, or contraindication to at least 1 of the following: acetaminophen or opioid analgesics or topical analgesics (capsaicin, etc.)

GENERIC: CHOLINE FENOFIBRATE

BRAND: TRILIPIX[®]

INDICATION:

- (1) Hypercholesterolemia, Hypertriglyceridemia

Criteria:

- (a) Failure of generic fenofibrate 48, 54, 154 or 160mg after a period of at least two months on the maximum dose appropriate and tolerated by the patient.

Prior Authorization Guidelines

GENERIC: CLOXACILLIN SODIUM

INDICATION:

- (1) Treatment of infections due to penicillinase-producing staphylococci

Criteria:

- (a) Diagnosis of staphylococcal infection; **and**
- (b) Failure of dicloxacillin sodium.

GENERIC: CYANOCOBALAMIN (HYDROXYCOBALAMIN)

BRAND: VITAMIN B-12[®]

INDICATION:

- (1) Vitamin B-12 deficiency

Criteria:

- (a) Patients who lack intrinsic factor; **or**
- (b) Patients who are on long-term PPI therapy; **or**
- (c) Patients with a partial or complete gastrectomy.

** For injectable medications administered by a healthcare professional, please refer to the "Specialty Medication Guidelines" in the beginning of this formulary.*

GENERIC: DABIGATRAN ETEXILATE MESYLATE

BRAND: PRADAXA[®]

INDICATION:

- (1) Reduce the risk of stroke and systemic embolism in patients with non-vascular atrial fibrillation.

Criteria:

- (a) Diagnosis of non-vascular atrial fibrillation; **and**
- (b) Must have recent CrCl levels or Scr and current patient weight; **and**
- (c) No active pathological bleeding; **and**
- (d) Must have tried and failed or intolerant to Warfarin

NOTE: Conversion to Pradaxa:

- (a) From Warfarin: discontinue warfarin and start pradaxa when INR < 2.0
- (b) From Parenteral Anticoagulants: start Pradaxa 0-2 hrs prior to next scheduled dose of parenteral anticoagulant, or at the time of discontinuation of continuous parenteral drug (e.g. heparin)

Prior Authorization Guidelines

GENERIC: DALFAMPRIDINE

BRAND: AMPYRA[®]

INDICATION:

(1) Improved walking speed in patients with multiple sclerosis

Criteria:

- (a) Diagnosis of multiple sclerosis; **and**
- (b) Prescribed by a neurologist; **and**
- (c) Currently taking a disease modifying drug for multiple sclerosis (Avonex, Betaseron, Copaxone, Extavia, Gilenya, Rebif, or Tysabri)

**Renewals will require documented improvement in walking speed (demonstrated improvement in timed 25 foot walk)*

GENERIC: DANTROLENE

BRAND: DANTRIUUM[®]

INDICATION:

(1) Spasticity resulting from upper motor neuron disorders

Criteria:

- (a) Demonstrated failure of, or intolerance to, Baclofen (Lioresol[®]).

GENERIC: DARBEOETIN ALFA

BRAND: ARANESP[®]

INDICATIONS:

- (1) Anemia with cancer chemotherapy (nonmyeloid)
- (2) Anemia due to chronic renal failure

Criteria:

- (a) Ensure patient's iron stores are adequate (Ferritin \geq 100 ng/mL and/or Transferrin saturation \geq 20%) or patient is being treated with iron; **and**
- (b) Adequate blood pressure control; **and**

Chronic kidney disease patients:

- (a) Initiate treatment when hemoglobin is $<$ 10g/dL; **or**

Anemia due to chemotherapy in cancer:

- (a) Initiate treatment only if hemoglobin is $<$ 10g/dL; **and**
- (b) Anticipated duration of myelosuppressive chemotherapy is \geq 2 months

Prior Authorization Guidelines

For renewals:

(a) **Chronic kidney disease patients:**

- (1) With dialysis Hbg <11; or
- (2) Without dialysis Hbg <10

(b) **Anemia due to chemotherapy in cancer patients:**

- (1) Hbg <11

GENERIC: DESMOPRESSIN

BRAND: DDAVP[®]

INDICATIONS:

- (1) Central cranial diabetes insipidus (CCDI)
- (2) Primary nocturnal enuresis

Criteria:

- (a) Diagnosis of CCDI; **or**
- (b) For the treatment of enuresis, age 6 to 18 years; **and**
- (c) Failure of behavior modification for 6 months (e.g., alarms, no beverages after 5pm, special diapers etc.).

** Renewals for the indication of nocturnal enuresis will require the documentation of a retrial of behavior modification.*

GENERIC: DONEPEZIL

BRAND: ARICEPT[®]

INDICATION:

- (1) Alzheimer's disease: for the treatment of dementia.

Criteria:

- (a) Dementia must be confirmed by clinical evaluation

GENERIC: ENTACAPONE

BRAND: COMTAN[®]

INDICATION:

- (1) As an adjunct to levodopa/carbidopa to treat patients with idiopathic Parkinson's disease

Criteria:

- (a) Diagnosis of idiopathic Parkinson's disease; **and**
- (b) Patient is receiving concomitant levodopa/carbidopa therapy.

Prior Authorization Guidelines

GENERIC: EPOETIN ALFA

BRAND: PROCRIT[®], EPOGEN[®]

INDICATIONS:

- (1) Anemia with cancer chemotherapy (nonmyeloid)
- (2) Anemia due to chronic renal failure
- (3) Anemia of HIV infection associated with zidovudine
- (4) Reduction of allogeneic blood transfusion for elective, noncardiac, nonvascular surgery

Criteria:

- (a) Patient's iron stores are adequate (Ferritin \geq 100 ng/mL and/or Transferrin saturation \geq 20%) or patient is being treated with iron; **and**
- (b) Adequate blood pressure control

Chronic kidney disease patients:

- (a) Initiate treatment when hemoglobin is <10 g/dL (3 month approval)

Anemia due to chemotherapy in cancer patients:

- (a) Initiate treatment only if hemoglobin <10 g/dL and anticipated duration of myelosuppressive chemotherapy is \geq 2 months

Anemia due to zidovudine in HIV-infected patients:

- (a) Initiate treatment when hemoglobin is <10 g/dL

Surgical procedure - Transfusion of blood product, Allogeneic; Prophylaxis:

- (a) Patient's pre-operative Hgb >10 to ≤ 13 g/dL (14 day approval)

For renewals:

Chronic kidney disease patients:

- (a) With dialysis Hgb <11
- (b) Without dialysis Hgb <10

Anemia due to chemotherapy in cancer patients:

- (a) Hgb <11

Anemia due to zidovudine in HIV-infected patients:

- (a) Hgb <11

Prior Authorization Guidelines

GENERIC: ETANERCEPT

BRAND: ENBREL[®]

INDICATION:

- (1) Moderate to severely active rheumatoid arthritis
- (2) Moderate to severely active polyarticular juvenile rheumatoid arthritis
- (3) Psoriatic spondylitis
- (4) Ankylosing spondylitis
- (5) Plaque psoriasis

Criteria:

- (a) The patient had a NEGATIVE tuberculin skin test, or if positive, has received treatment for latent TB prior to Enbrel therapy; **and**
- (b) The patient does not have a clinically important active infection

Additional Criteria for RA:

- (a) The patient has failed or is intolerant to one formulary NSAID **and**
- (b) The patient has failed or is intolerant to one formulary DMARD

Additional Criteria for Plaque Psoriasis:

- (a) Involvement of $\geq 10\%$ body surface area (BSA)

GENERIC: EXENATIDE

BRAND: BYETTA[®]

INDICATION:

- (1) Adjunctive therapy of type 2 diabetes mellitus

Criteria:

- (a) Diagnosis of type 2 diabetes; **and**
- (b) Failure or intolerance to sulfonylureas and/or metformin at optimal dosing. Failure defined as Hemoglobin A1c ≥ 7.0 ; **and**
- (c) Patient ≥ 18 years of age

Prior Authorization Guidelines

GENERIC: EZETIMIBE

BRAND: ZETIA[®]

INDICATIONS:

- (1) Hypercholesterolemia
- (2) Sitosterolemia

Criteria:

- (a) Diagnosis of sitosterolemia; **or**
- (b) For the diagnosis of hypercholesterolemia, failure of optimal dosing/duration or intolerance/contraindication to 2 formulary anti-lipid agents (with at least one agent being a statin)

GENERIC: EZETIMIBE/SIMVASTATIN

BRAND: VYTORIN[®]

INDICATIONS:

- (1) Hypercholesterolemia

Criteria:

- (a) The diagnosis of hypercholesterolemia, failure of optimal dosing/duration or intolerance/contraindication to 2 formulary anti-lipid agents (with at least one agent being a statin)

GENERIC: FENOFIBRATE

BRAND: LIPOFEN[®], TRIGLIDE[®]

INDICATION:

- (1) Hypercholesterolemia, Hypertriglyceridemia

Criteria:

- (a) Failure of generic fenofibrate 48, 54, 154, or 160mg after a period of at least two months on the maximum dose appropriate and tolerated by the patient.

GENERIC: FENOFIBRATE MICRONIZED

BRAND: ANTARA[®]

INDICATION:

- (1) Hypercholesterolemia, Hypertriglyceridemia

Criteria:

- (a) Failure of generic fenofibrate 54 or 160mg after a period of at least two months on the maximum dose appropriate and tolerated by the patient.

Prior Authorization Guidelines

GENERIC: FENOFIBRIC ACID

BRAND: TRILIPIX[®]

INDICATION:

- (1) Hypercholesterolemia, Hypertriglyceridemia

Criteria:

- (b) Failure of generic fenofibrate 54 or 160mg after a period of at least two months on the maximum dose appropriate and tolerated by the patient.

GENERIC: FENTANYL TRANSDERMAL PATCH

BRAND: DURAGESIC[®]

INDICATION:

- (1) Persistent, moderate to severe chronic pain OR cancer-related pain that requires continuous, around-the-clock opioid (narcotic) administration for an extended period of time

Criteria:

- (a) Diagnosis of persistent, moderate to severe chronic or cancer-related pain requiring continuous, around-the-clock opioid administration for an extended period of time; **and**
(b) Patient unable to take medications by mouth; **or**
(c) Failure of or intolerance/contraindication to a long-acting oral opiate (narcotic) medication (controlled-release morphine, oxycodone, or oxymorphone)

GENERIC: FILGRASTIM

BRAND: NEUPOGEN[®]

INDICATIONS:

- (1) Prevention of neutropenia in patients receiving myelosuppressive chemotherapy for non-myeloid malignancies
(2) Patients undergoing peripheral blood progenitor cell collection and therapy
(3) Patients with severe chronic neutropenia

Criteria:

- (a) The patient is undergoing peripheral blood progenitor cell collection and therapy; **or**
(b) Diagnosis of severe chronic neutropenia with an absolute neutrophil count (ANC) < 1,000; **or**

Prior Authorization Guidelines

- (c) ANC nadir of < 1,000 neutrophils to previous chemotherapy. Once this has been documented, approval will be given to prophylax for all future chemo cycles.

** For injectable medications administered by a healthcare professional, please refer to the “Specialty Medication Guidelines” in the beginning of this formulary.*

** Please indicate estimated duration of therapy.*

GENERIC: FLUCONAZOLE

BRAND: DIFLUCAN[®]

(PA required after 1x 150mg tablet dispensed)

INDICATIONS:

- (1) Vaginal candidiasis
- (2) Cryptococcal meningitis
- (3) Serious systemic candidal infections
- (4) Oropharyngeal and esophageal candidiasis

Criteria:

- (a) Any of the above diagnoses; **except**
- (b) For the diagnosis of oropharyngeal candidiasis, failure of nystatin therapy; **and**
- (c) For the diagnosis of vaginal candidiasis, patients who are immunocompromised and/or have recurrent or refractory infections.

GENERIC: GALANTAMINE HYDROBROMIDE

BRAND: RAZADYNE[®], RAZADYNE ER[®]

INDICATION:

- (1) Alzheimer’s disease: for the treatment of dementia

Criteria:

- (a) Confirmation by clinical evaluation

GENERIC: GATIFLOXACIN

BRAND: ZYMAXID[®]

INDICATION:

- (1) Bacterial conjunctivitis

Criteria:

- (a) Failure of, contraindication to, or intolerance to ciprofloxacin ophthalmic formulation.

Prior Authorization Guidelines

GENERIC: GLATIRAMER ACETATE

BRAND: COPAXONE[®]

INDICATION:

- (1) Relapsing-remitting Multiple Sclerosis
- (2) To prevent or slow the development of clinically definite Multiple Sclerosis in patients who have experienced a first clinical episode and have MRI features consistent with Multiple Sclerosis

Criteria:

- (a) Prescribed by neurologist; **and**
- (b) Not requesting combination therapy of any 2 agents together: Copaxone, Novantrone, Betaseron, Avonex, Tysabri or Rebif

GENERIC: INTERFERON ALPHA

BRAND: ROFERON-A[®], INTRON-A[®], and ALFERON[®]

INDICATIONS:

- (1) Hairy cell leukemia
- (2) AIDS-related Kaposi's sarcoma
- (3) Chronic hepatitis B or C
- (4) Malignant melanoma

Criteria:

- (a) Any of the above diagnoses.

**For injectable medications administered by a healthcare professional, please refer to the "Specialty Medication Guidelines" in the beginning of this formulary.*

GENERIC: INTERFERON BETA

BRAND: AVONEX[®], BETASERON[®], REBIF[®]

INDICATIONS:

- (1) Diagnosis of a relapsing form of Multiple Sclerosis; **or**
- (2) First clinical demyelinating event with MRI evidence consistent with Multiple Sclerosis

Criteria:

- (a) Prescribed by neurologist; **and**
- (b) If patient has a history of or is currently being treated for severe psychiatric disorders, suicidal ideation or severe depression, this condition is well controlled; **and**
- (c) Not requesting combination of any 2 agents together: Copaxone, Novantrone, Betaseron, Avonex, Tysabri or Rebif

Prior Authorization Guidelines

** For injectable medications administered by a healthcare professional, please refer to the “Specialty Medication Guidelines” in the beginning of this formulary.*

GENERIC: ISOSORBIDE MONONITRATE

BRAND: IMDUR[®]

INDICATION:

(1) Prevention of angina pectoris

Criteria:

(a) Failure of formulary nitrates.

GENERIC: ITRACONAZOLE

BRAND: SPORANOX[®]

INDICATIONS:

(1) Histoplasmosis infections

(2) Aspergillosis infections

(3) Blastomycosis

Criteria:

(a) Any of the above diagnoses.

GENERIC: LEUPROLIDE

BRAND: LUPRON[®]

INDICATIONS:

(1) Advanced prostate cancer

(2) Central precocious puberty

(3) Endometriosis

(4) Uterine leiomyomata (fibroids)

Criteria:

(a) Diagnosis of advanced prostate cancer, precocious puberty or fibroids; **or**

(b) For the diagnosis of endometriosis, failure of NSAIDS **and** oral contraceptives **or** endometriosis diagnosed by laparoscopy.

**Note: This agent is ordinarily administered at the physician’s office. For injectable medications administered by a healthcare professional, please refer to the “Specialty Medication Guidelines” in the beginning of this formulary.*

Prior Authorization Guidelines

GENERIC: LIDOCAINE PATCH 5%

BRAND: LIDODERM[®]

INDICATION:

- (1) Relief of pain associated with post-herpetic neuralgia

Criteria:

- (a) Skin application site is intact **and**
(b) For the relief of pain associated with post-herpetic neuralgia **or**
(c) For non-neuropathic pain, failure, adverse reaction, or
contraindication to two prescribed prescription analgesics

GENERIC: LIRAGLUTIDE

BRAND: VICTOZA[®]

INDICATION:

- (1) Adjunct to diet and exercise to improve glycemic control in patients with type II diabetes mellitus

Criteria:

- (a) Diagnosis of type II diabetes mellitus; **and**
(b) Must be under the care of a healthcare provider skilled with the use of insulin and supported by a diabetes educator
(c) Must have tried at least 2 antidiabetic agents such as metformin, sulfonylureas, thiazolidinedione or insulin and not achieved adequate glycemic control despite treatment or intolerant to other antidiabetic medications; **and**
(d) Must have tried and failed or intolerant to treatment with Byetta; **and**
(e) NO personal or family history of medullary thyroid carcinoma

GENERIC: MEMANTINE

BRAND: NAMENDA[®]

INDICATION:

- (1) Alzheimer's disease: for treatment of moderate-to-severe cases of dementia

Criteria:

- (a) Dementia must be confirmed by clinical evaluation; **and**
(b) Documented dementia is either moderate or severe

Prior Authorization Guidelines

GENERIC: METRONIDAZOLE VAGINAL GEL

BRAND: METROGEL®

INDICATION:

(1) Bacterial vaginosis

Criteria:

- (a) Pregnancy; **or**
- (b) Intolerance to oral metronidazole

GENERIC: MILNACIPRAN

BRAND: SAVELLA®

INDICATION:

(1) Moderate to severe fibromyalgia

Criteria:

- (a) Trial of two of the three below agents after a period of at least two months on the maximum dose appropriate and tolerated by the patient:
 - (1) gabapentin
 - (2) venlafaxine
 - (3) one other evidence based effective agent (TCA therapy, SSRIs, tramadol, NSAIDs, cyclobenzaprine)

GENERIC: MOXIFLOXACIN

BRAND: AVELOX®

INDICATION:

- (1) Acute bacterial sinusitis
- (2) Acute bacterial exacerbations of chronic bronchitis
- (3) Mild to moderate pelvic inflammatory disease
- (4) Complicated/Uncomplicated skin and skin structure infections
- (5) Community-acquired pneumonia
- (6) Complicated intra-abdominal infections

Criteria:

In patients ≥ 18 years of age with any of the above listed indications when:

- (a) Cultures show sensitivity to Avelox® only; **or**
- (b) Patient discharged on Avelox® from the hospital and needs to complete regimen on an outpatient basis

Prior Authorization Guidelines

GENERIC: NAFARELIN

BRAND: SYNAREL[®]

INDICATIONS:

- (1) Central precocious puberty
- (2) Endometriosis

Criteria:

- (a) Diagnosis of central precocious puberty; **or**
- (b) For the diagnosis of endometriosis in patients ≥ 18 years of age, failure of NSAIDs **and** oral contraceptives, **or** endometriosis diagnosed by laparoscopy.

GENERIC: NUTRITIONAL SUPPLEMENTS

BRAND: ENSURE[®], PEDIASURE[®], BOOST[®], VIVONEX[®]

INDICATION:

- (1) Nutritional supplementation

Criteria:

- (a) Patient must have enteral access via one of the following: nasogastric (NG) tube, nasoduodenal (ND) tube, nasojejunal (NJ) tube, percutaneous endoscopic gastrostomy (PEG) or percutaneous endoscopic jejunostomy (PEJ).

GENERIC: OCTREOTIDE

BRAND: SANDOSTATIN[®]

INDICATIONS:

- (1) Symptomatic treatment of severe diarrhea and flushing episodes associated with metastatic carcinoid tumors
- (2) Profuse, watery diarrhea associated with vasoactive intestinal peptide (VIP) secreting tumors
- (3) To reduce the blood levels of growth hormone and IGF-I associated with acromegaly

Criteria:

- (a) Any of the above diagnoses; **and**
- (b) For the diagnosis of acromegaly, the patient has had an inadequate response to, or can not be treated with surgical resection, pituitary irradiation **and** bromocriptine at maximally tolerated doses.

**For injectable medications administered by a healthcare professional, please refer to the “Specialty Medication Guidelines” in the beginning of this formulary.*

Prior Authorization Guidelines

GENERIC: ONDANSETRON ODT AND SOLUTION

BRAND: ZOFRAN[®]

INDICATIONS:

- (1) Chemotherapy induced nausea and vomiting
- (2) Post-operative nausea and vomiting
- (3) Radiation induced nausea and vomiting

Criteria:

- (a) For patients who have a contraindication or failure of regular release ondansetron tablets

GENERIC: OXYCODONE, CONTROLLED-RELEASE

BRAND: OXYCONTIN[®]

INDICATIONS:

- (1) Persistent, moderate to severe chronic pain **or** cancer-related pain that requires continuous, around-the-clock opioid (narcotic) administration for an extended period of time; not intended as an as-needed analgesic.

Criteria:

- (a) Persistent, moderate to severe chronic pain **or** cancer-related pain that requires around-the-clock analgesia for an extended period of time; **and**
- (b) For chronic pain, failure, intolerance, or contraindication to at least 2 short-acting formulary narcotic analgesics
- (c) For cancer pain, failure intolerance, or contraindication to controlled-release morphine (MS Contin, others)

GENERIC: PALIVIZUMAB

BRAND: SYNAGIS[®]

INDICATION:

- (1) Prevention of serious lower respiratory disease caused by respiratory syncytial virus (RSV)

Criteria:

- (a) Administration within RSV season (Nov-Apr); **and**
- (b) Pt < 2 yrs of age at start of RSV season with chronic lung disease that has required treatment (supplemental oxygen, bronchodilator, diuretic or corticosteroid) within prior 6 months **or**
- (c) Pt born \leq 28 weeks gestation and is \leq 12 months at the start of the RSV season **or**

Prior Authorization Guidelines

- (d) Pt born between 29-32 weeks gestation and is ≤ 6 months at the start of the RSV season **or**
- (e) Pt ≤ 24 months of age at the start of the RSV season with hemodynamically significant congenital heart disease, including one of the following:
 - (1) Receiving medication to control congestive heart failure; **or**
 - (2) With moderate to severe pulmonary artery hypertension; **or**
 - (3) With cyanotic congenital heart disease; **or**
- (f) Pt born between 32-35 weeks gestation, and is ≤ 3 months at the start of the RSV season **and** has one of the following risk factors:
 - (1) Child care attendance; **or**
 - (2) Siblings less than 5 years **and** children born between 32-35 weeks receive a maximum of 3 doses; **or**
- (g) Is the patient born before 35 weeks of gestation and has either congenital abnormalities of the airway or a neuromuscular condition that compromises handling of respiratory secretions during the first year of life?

Once the prior authorization is received, please contact the Synagis line below:

Phone = 866-807-0516

Fax =800-784-6283

GENERIC: PANTOPRAZOLE

BRAND: PROTONIX[®]

INDICATION:

- (1) Gastric hypersecretion, pathological conditions including Zollinger-Ellison Syndrome
- (2) Erosive esophagitis - gastroesophageal reflux disease
- (3) Erosive esophagitis, maintenance therapy - gastroesophageal reflux disease

Criteria:

- (a) Failure, intolerance, or contraindication to at least 1 formulary PPI after a period of at least two months on the maximum dose appropriate and tolerated by the patient.

Prior Authorization Guidelines

GENERIC: PEGINTERFERON ALFA-2A

BRAND: PEGASYS[®]

INDICATION:

- (1) Use in combination with ribavirin for the treatment of chronic hepatitis C
- (2) Treatment of chronic hepatitis C in patients coinfecting with HIV whose HIV is clinically stable.
- (3) Treatment of patients with HBeAg positive and HBeAg negative chronic hepatitis B

Criteria:

(In combination with ribavirin)

- (a) Diagnosis as indicated above including any applicable labs and/or tests
- (b) Clinically documented chronic hepatitis C with detectable HCV RNA levels > 50 IU/mL
- (c) Age \geq 3 years
- (d) Liver biopsy (unless contraindicated) indicates some fibrosis and inflammatory necrosis
- (e) Intolerant to Peg-Intron
- (f) If HIV positive, patient is clinically stable.

(For chronic hepatitis B)

- (a) Documented HBeAg positive or negative chronic hepatitis B
- (b) Compensated liver disease
- (c) Evidence of viral replication
- (d) Evidence of liver inflammation
- (e) Not contraindicated

GENERIC: PEGINTERFERON ALFA-2B

BRAND: PEG-INTRON[®]

INDICATION:

- (1) Use in combination with ribavirin for the treatment of chronic hepatitis C
- (2) Treatment of chronic hepatitis C in patients coinfecting with HIV whose HIV is clinically stable.

Criteria:

(In combination with ribavirin)

- (a) Diagnosis as indicated above including any applicable labs and/or tests

Prior Authorization Guidelines

- (b) Clinically documented chronic hepatitis C with detectable HCV RNA levels > 50 IU/mL
- (c) Age \geq 3 years
- (d) Liver biopsy (unless contraindicated) indicates some fibrosis and inflammatory necrosis
- (e) Intolerant to Peg-Intron
- (f) If HIV positive, patient is clinically stable.

GENERIC: PENTOXIFYLLINE

BRAND: TRENTAL[®]

INDICATION:

- (1) Intermittent claudication

Criteria:

- (a) Pain on walking **or** ABI < 0.8; **or**
- (b) Diabetic foot ulcer; **or**
- (c) Gangrene; **or**
- (d) Risk of, or existing, amputation.

GENERIC: PIMECROLIMUS

BRAND: ELIDEL[®]

INDICATION:

- (1) Second-line therapy for the short-term and non-continuous chronic treatment of mild to moderate atopic dermatitis in non-immunocompromised adults and children 2 years of age and older, who have failed to respond adequately to other topical prescription treatments, or when treatments are not advisable.

Criteria:

- (a) Documented failure of optimal dosing/adequate duration; **or**
- (b) Intolerance or contraindication to at least one formulary topical corticosteroid; **and**
- (c) Diagnosis of mild to moderate atopic dermatitis; **and**
- (d) Using for short-term and non-continuous treatment.

Prior Authorization Guidelines

GENERIC: RALOXIFENE

BRAND: EVISTA®

INDICATION:

- (1) Treatment and prevention of osteoporosis in postmenopausal women

Criteria:

- (a) Personal or family history of breast cancer; **or**
- (b) Intolerable side effects to at least one formulary estrogen.

GENERIC: RIBAVIRIN

BRAND: REBETOL®

INDICATION:

- (1) Indicated **only** in combination with a recombinant interferon alfa-2a or alfa-2b product for the treatment of chronic hepatitis C.

Criteria:

- (a) Diagnosis of chronic hepatitis C; **and**
- (b) Patient is receiving concomitant recombinant interferon alfa-2a or alfa-2b therapy.

GENERIC: RILUZOLE

BRAND: RILUTEK®

INDICATION:

- (1) Amyotrophic lateral sclerosis (ALS)

Criteria:

- (a) Diagnosis of ALS.

GENERIC: RIVASTIGMINE TARTRATE

BRAND: EXELON®

INDICATION:

- (1) Alzheimer's disease: for the treatment of dementia

Criteria:

- (a) Confirmation by clinical evaluation

Prior Authorization Guidelines

GENERIC: RIZATRIPTAN

BRAND: MAXALT®

INDICATION:

(1) Acute treatment of migraine headache

Criteria:

- (a) Failure of, intolerance to, or contraindication to one traditional formulary agent (NSAID's, ergotamine, or combination analgesic); **or**
- (b) Unsuccessful concurrent or previous use of migraine prophylaxis medications (e.g., beta-blockers, calcium channel blockers, tri-cyclic antidepressants or anticonvulsants); **and**
- (c) Patient is not currently using ergotamine or another 5-HT1 Receptor Agonist.

GENERIC: ROPINROLE

BRAND: REQUIP®

INDICATION:

- (1) For the treatment of signs and symptoms of idiopathic Parkinson's disease.
- (2) Moderate to severe primary Restless Legs Syndrome.

Criteria:

- (a) Diagnosis of idiopathic Parkinson's disease; **or**
- (b) Diagnosis of Restless Leg Syndrome and normal iron stores (serum ferritin and/or iron-binding saturation)

GENERIC: ROSIGLITAZONE MALEATE

BRAND: AVANDIA®

INDICATION:

- (1) Type 2 diabetes: As an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus

Criteria:

- (a) Blood sugar not controlled with any other antidiabetic medications; **and**
- (b) Failure or contraindication to use an Actos-containing regimen.

Prior Authorization Guidelines

GENERIC: ROSIGLITAZONE MALEATE/GLIMEPIRIDE

BRAND: AVANDARYL®

INDICATION:

- (1) Type 2 diabetes: As an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus

Criteria:

- (a) Blood sugar not controlled with any other antidiabetic medications **and**
- (b) Failure or contraindication to use an Actos-containing regimen.

GENERIC: ROSIGLITAZONE MALEATE/METFORMIN

BRAND: AVANDAMET®

INDICATION:

- (1) Type 2 diabetes: As an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus

Criteria:

- (a) Blood sugar not controlled with any other antidiabetic medications **and**
- (b) Failure or contraindication to use an Actos-containing regimen.

GENERIC: ROSUVASTATIN CALCIUM

BRAND: CRESTOR®

INDICATION:

- (1) Primary prevention of CV disease in patients with multiple risk factors for CHD, diabetes, peripheral vascular disease, history of stroke, or other cerebrovascular disease.

Criteria:

- (a) Failure of at least two generic formulary statins after a period of at least two months on the maximum dose appropriate and tolerated by the patient.

Prior Authorization Guidelines

GENERIC: SALMETEROL/FLUTICASONE

BRAND: ADVAIR/ADVAIR HFA®

INDICATION:

- (1) Long-term, twice-daily maintenance treatment of asthma in patients 4 years of age and older.

Criteria:

- (a) Currently on, but not controlled by an inhaled corticosteroid
- (b) Twice daily maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease.

Criteria for the 250/50mg Strength:

- (a) The 250/50mg strength is the only approved strength for COPD **and**
- (b) The patient must be reevaluated after 6 months

**For members currently with an approved prior authorization for Advair, claims will process as long as the member has filled Advair within the last 3 months. No yearly renewal will be needed for compliant members. Prior authorization will be required for members new to the plan, new to Advair therapy, or with no claim history of Advair within the last 3 months.*

GENERIC: SALMETEROL XINAFOATE

BRAND: SEREVENT DISKUS®

INDICATION:

- (1) Maintenance treatment of asthma and prevention of bronchospasm in adults and children 4 years of age and older
- (2) Prevention of exercise-induced bronchospasm in patients 4 years of age and older
- (3) Serevent Diskus® is indicated for the maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease

Criteria:

- (a) Currently on but not controlled by an inhaled corticosteroid

Prior Authorization Guidelines

GENERIC: SIMVASTATIN 80mg

BRAND: ZOCOR

INDICATIONS:

- (1) Heterozygous or homozygous familial hypercholesterolemia
- (2) Familial type 3 hyperlipoproteinemia
- (3) Hypertriglyceridemia
- (4) Primary hypercholesterolemia, or mixed hyperlipidemia
- (5) Decrease cardiovascular event risk in patients with high coronary event risk
- (6) Cerebrovascular accident prophylaxis

Criteria:

- (a) Age \leq 65 years
- (b) Male gender (female gender predisposed to myopathy including rhabdomyolysis)
- (c) Controlled hypothyroidism
- (d) Normal renal function
- (e) Documentation of all cholesterol lowering agents tried and failed must be provided.

GENERIC: SOMATROPIN

BRAND: HUMATROPE®

INDICATIONS:

- (1) Growth failure in children due to inadequate growth hormone (GH) secretion
- (2) Idiopathic short stature in children defined by height standard deviation (SD) score less than or equal to -2.25 and growth rate not likely to attain normal adult height
- (3) Short stature in children associated with Turner syndrome

Criteria:

- (a) Patient with open epiphyses (as confirmed by radiograph of wrist and hand) who has not reached final height; **and**
- (b) Medication prescribed by an endocrinologist; **and**
- (c) Patient meets one of the following criteria:
 - (1) Growth Hormone Deficiency (GHD) with diagnosis confirmed by one of the following:
 - i. Severe short stature defined as patient's height at \geq 2 SD below the population mean

Prior Authorization Guidelines

- ii. Patient's height ≥ 1.5 SD below the midparental height (average of mother's and father's heights)
 - iii. Patient's height ≥ 2 SD below the mean and a 1-year height velocity more than 1 SD below the mean for chronologic age or (in children 2 years of age or older) a 1-year decrease of more than 0.5 SD in height
 - iv. In the absence of short stature, a 1-year height velocity more than 2 SD below the mean or a 2-year height velocity more than 1.5 SD below the mean (may occur in GHD manifesting during infancy or in organic, acquired GHD)
 - v. Signs indicative of an intracranial lesion
 - vi. Signs of multiple pituitary hormone deficiencies
 - vii. Neonatal symptoms and signs of GHD
- (2) Idiopathic short stature with patient's height at ≥ 2.25 SD below the mean height for normal children of the same age and gender
 - (3) Short stature associated with Turner syndrome and height below the 5th percentile of normal growth curve

* *To continue therapy, requests will be reviewed every six months.*

* *For injectable medications administered by a healthcare professional, please refer to the "Specialty Medication Guidelines" in the beginning of this formulary.*

Prior Authorization Guidelines

GENERIC: SUCCIMER

BRAND: CHEMET®

INDICATIONS:

- (1) Treatment of lead poisoning in children with blood lead levels > 45 mcg/dl
- (2) Unlabeled uses: Succimer may be beneficial in the treatment of other heavy metal poisonings

Criteria:

- (a) Diagnosis of lead poisoning with blood levels > 45mcg/dl; **and**
- (b) Child is hospitalized; **or**
- (c) Child was started on the medication in the hospital and needs to continue upon discharge.

GENERIC: SUCRALFATE SUSPENSION

BRAND: CARAFATE®

INDICATIONS:

- (1) Gastric ulcers
- (2) Duodenal ulcers
- (3) Gastritis
- (4) GERD

Criteria:

- (a) For patients who have a contraindication or failure of sucralfate tablets

GENERIC: TELAPREVIR

BRAND: INCIVEK®

INDICATION:

- (1) Treatment of chronic hepatitis C genotype 1 used in combination with peginterferon alfa and ribavirin

Criteria:

- (a) Diagnosis of chronic hepatitis C genotype 1; **and**
- (b) Diagnosis of compensated liver disease; **and**
- (c) No previous treatment (full or partial course) of Incivek or Victrelis; **and**
- (d) Patient has been counseled on the importance of medication adherence and is willing to adhere to the regimen for the full course of therapy; **and**

Prior Authorization Guidelines

- (e) The patient must have completed 4 weeks of peginterferon and ribavirin therapy (treatment weeks 1 through 4); **and**
- (f) HCV-RNA levels must be drawn at treatment weeks 4, 12, and 24
- (g) Females of child bearing potential must meet the following parameters:
 - (1) A recent negative pregnancy test; **and**
 - (2) Been counseled on the teratogenic effects of triple therapy; **and**
 - (3) Is willing to practice contraception during and for 6 months after completion of therapy

GENERIC: THROMBIN

BRAND: THROMBIN

INDICATION:

- (1) Hemostasis

Criteria:

- (a) Diagnosis of a bleeding disorder

GENERIC: VARENCLINE

BRAND: CHANTIX®

INDICATION:

- (1) Management of smoking cessation

Criteria:

- (a) Physician has confirmed that the patient has no history of psychiatric illness (including, but not limited to, depression).
- (b) Physician has counseled the patient to self-monitor mood and behavior while on Chantix, and to contact their physician immediately if they experience any changes in mood or behavior.
- (c) Physician must provide evidence that patient has completed smoking cessation class.

Quantity Limit of 12 weeks of therapy per 12-month period

Prior Authorization Guidelines

GENERIC: ZOLMITRIPTAN TABLETS

BRAND: ZOMIG®

INDICATION:

(1) Acute treatment of migraine headache

Criteria:

- (a) Failure of, intolerance to, or contraindication to one traditional formulary agent (NSAID, ergotamine, or combination analgesic); **or**
- (b) Unsuccessful concurrent or previous use of migraine prophylaxis medications (e.g., beta-blockers, calcium channel blockers, tri-cyclic antidepressants or anticonvulsants); **and**
- (c) Patient is not currently using ergotamine or another 5-HT₁ Receptor Agonist

Index

| <u>Product Name</u> | <u>Page</u> | <u>Product Name</u> | <u>Page</u> |
|---------------------------------|-------------|-------------------------------------|-------------|
| A/B OTIC | 18 | Amlodipine & Atorvastatin | 8 |
| Acamprosate | 17 | Amlodipine & Benazepril* | 7 |
| Acarbose* | 5 | Amlodipine* | 7 |
| ACCUNEB | 9 | Ammonium Lactate* | 19 |
| ACCUPRIL | 7 | Amox & K Clav* | 1 |
| Acetaminophen w/ Codeine* | 13 | Amoxicillin* | 1 |
| Acetaminophen w/ Hydrocodone* | 13 | AMOXIL | 1 |
| Acetaminophen* | 12 | Ampicillin* | 1 |
| ACETASOL HC | 18 | AMPYRA | 20 |
| Acetazolamide* | 8 | Amylase-Lipase-Protease | 11 |
| ACETEST | 19 | Amylase-Lipase-Protease Reg.Rls | 11 |
| Acetone Tablets | 19 | ANAPROX | 13 |
| Acetone Test* | 19 | ANDROID | 4 |
| Acetylcysteine* | 9 | ANSAID | 13 |
| ACTONEL | 6 | ANTABUSE | 17 |
| ACTOPLUS MET | 5 | ANTARA | 8 |
| ACTOS | 5 | Antihemophilic Factor (Human) | 16 |
| Acyclovir Topical | 19 | Antihemophilic Factor (Recombinate) | 16 |
| Acyclovir* | 3 | Antiinhibitor Coagulant Complex | 16 |
| ADALAT CC | 7 | Antithrombin III (Human) | 16 |
| Adalimumab | 20 | ANTIVERT | 11 |
| ADVAIR/HFA | 9 | ANUSOL-HC | 18 |
| ADVICOR | 8 | APAP/Caffeine/Butalbital* | 12 |
| AK-TRACIN | 17 | APRESOLINE | 7 |
| AI Hydrox-Mag Carb* | 10 | APRI | 4 |
| ALAVERT | 9 | ARALEN | 2 |
| Albendazole | 2 | ARANESP | 16 |
| ALBENZA | 2 | ARICEPT | 17 |
| ALBUTEROL NEBULIZER SOLN | 9 | ASACOL | 11 |
| Albuterol* | 9 | ASPIRIN BUFFERED | 12 |
| Albuterol-Ipratropium | 9 | Aspirin Enteric Coated* | 12 |
| ALCOHOL PADS | 20 | Aspirin w/ Codeine* | 13 |
| Alcohol Swabs* | 20 | Aspirin with Buffers* | 12 |
| ALDACTAZIDE | 8 | Aspirin zero order* | 12 |
| ALDACTONE | 8 | Aspirin/Caffeine/Butalbital* | 12 |
| Alendronate* | 6 | ASTELIN | 9 |
| Alendronate & Chloecalciferol | 6 | Atenolol* | 6 |
| ALFERON N | 4 | Atenolol & Chlorthalidone* | 7 |
| ALKERAN | 3 | Atorvastatin* | 8 |
| ALLEGRA | 9 | Atropine Sulfate* | 18 |
| ALLEGRA-D | 9 | ATROVENT HFA | 9 |
| Allopurinol* | 13 | ATROVENT/NASAL | 9 |
| ALOMIDE | 17 | AUGMENTIN | 1 |
| ALPHANATE | 16 | AVALIDE | 7 |
| ALTACE | 7 | AVANDAMET | 5 |
| Aluminum & Magnesium Hydroxide* | 10 | AVANDARYL | 5 |
| ALUMINUM HYDROXIDE | 10 | AVANDIA | 5 |
| Aluminum Hydroxide Gel* | 10 | AVAPRO | 7 |
| Amantadine* | 3 | AVC | 12 |
| Amantadine* | 14 | AVELOX | 1 |
| AMARYL | 5 | AVIANE | 4 |
| AMIGESIC | 12 | AVONEX | 4 |
| Aminophylline* | 10 | AYGESTIN | 5 |
| Amiodarone* | 7 | Azathioprine* | 20 |

| <u>Product Name</u> | <u>Page</u> | <u>Product Name</u> | <u>Page</u> |
|------------------------------------|-------------|------------------------------|-------------|
| Azelastine | 9 | Calcipotriene* | 19 |
| Azithromycin* | 1 | Calcitonin (Salmon) | 6 |
| AZMACORT | 9 | Calcitriol* | 15 |
| AZULFIDINE | 2 | Calcium Acetate* | 15 |
| AZULFIDINE | 11 | Calcium Carbonate* | 10 |
| Bacitracin* | 17 | Calcium Carbonate* | 15 |
| Bacitracin* | 18 | Calibration solution* | 20 |
| Bacitracin-Polymyxin B* | 17 | CAMILA | 4 |
| Bacitracin-Polymyxin-Neomycin-HC* | 17 | CAMPRAL | 17 |
| Baclofen* | 14 | Capecitabine | 3 |
| BACTRIM/DS | 2 | CAPOTEN | 7 |
| BACTROBAN | 18 | Captopril* | 7 |
| B-D INSULIN SYRINGE | 20 | CARAFATE TABLETS, SUSPENSION | 11 |
| Beclomethasone Dipropionate | 9 | Carbamide Peroxide* | 18 |
| BENADRYL | 9 | Carbidopa-Levodopa* | 14 |
| BENADRYL | 12 | CARDIZEM/CD | 7 |
| Benazepril* | 7 | CARDURA | 7 |
| BENTYL | 11 | Carvedilol* | 6 |
| BENZAC W | 19 | CATAPRES | 7 |
| Benzocaine & Antipyrine* | 18 | CEENU | 3 |
| Benzoyl Peroxide* | 19 | Cefaclor* | 1 |
| BEROCCA PLUS | 15 | Cefdinir | 1 |
| Betamethasone Dipropionate* | 19 | Cefixime | 1 |
| Betamethasone Valerate* | 19 | Cefprozil* | 1 |
| BETAPACE | 6 | CEFTIN | 1 |
| BETASERON | 4 | Ceftriaxone* | 1 |
| Betaxolol* | 17 | Cefuroxime* | 1 |
| Bethanechol* | 11 | CEFZIL | 1 |
| BETIMOL | 17 | CELEBREX | 13 |
| BETOPTIC/BETOPTIC S | 17 | Celecoxib | 13 |
| BIAXIN | 1 | CELLCEPT | 20 |
| BICILLIN | 1 | Cephalexin* | 1 |
| Bisacodyl* | 10 | Cephadrine* | 1 |
| Bismuth Subsalicylate* | 10 | Cetirizine* | 9 |
| BLEPH-10 | 17 | CHANTIX | 17 |
| BLEPHAMIDE | 17 | CHEMET | 20 |
| Blood Glucose Monitoring Tests* | 20 | CHILDS COMPLETE | 15 |
| Boceprevir | 3 | Chlorambucil | 3 |
| BONIVA | 6 | Chloroquine* | 2 |
| BOOST | 15 | Chlorothiazide* | 8 |
| Bromocriptine* | 14 | Chlorthalidone* | 8 |
| Brompheniramine / Pseudoephedrine* | 10 | Cholestyramine* | 8 |
| Budesonide* | 9 | Choline & Mag Salicylate* | 12 |
| Budesonide-Formoterol | 9 | CILOXAN | 17 |
| Buprenorphine Hcl* | 13 | CIPRO | 1 |
| Buprenorphine-Naloxone Hcl | 13 | Ciprofloxacin* | 1 |
| Busulfan | 3 | Ciprofloxacin* | 17 |
| Butabarbital | 12 | Clarithromycin* | 1 |
| BUTISOL | 12 | CLARITIN | 9 |
| Butoconazole Nitrate* | 12 | CLARITIN-D | 9 |
| BYETTA | 5 | CLEOCIN | 1 |
| CADUET | 8 | CLEOCIN | 12 |
| CAFERGOT | 14 | CLEOCIN | 19 |
| CALAN/SR | 7 | CLIMARA | 4 |
| Clindamycin Phosphate* | 19 | CYTOMEL | 5 |
| Clindamycin* | 1 | CYTOVENE | 2 |
| Clindamycin* | 12 | CYTOXAN | 3 |

| <u>Product Name</u> | <u>Page</u> | <u>Product Name</u> | <u>Page</u> |
|---------------------------------|-------------|----------------------------------|-------------|
| CLINITEST | 19 | Dabigatran | 16 |
| CLINORIL | 13 | Dalfampridine | 20 |
| Clobetasol Propionate* | 19 | Danazol* | 4 |
| Clonidine* | 7 | DANTRIUM | 14 |
| Clonidine | 17 | Dantrolene* | 14 |
| Clonidine & Chlorthalidone* | 7 | Dapsone* | 2 |
| Clopidogrel* | 16 | DARAPRIM | 3 |
| CLORPRES | 7 | Darbopoetin | 16 |
| Clotrimazole* | 12 | DARVOCET N-100 | 13 |
| Clotrimazole* | 18 | DDAVP | 6 |
| Cloxacillin Sodium* | 1 | DEBROX | 18 |
| COAL TAR SHAMPOO | 19 | DEMEROL | 13 |
| Codeine phosphate* | 13 | DEPO-PROVERA | 5 |
| Codeine sulfate* | 13 | Desmopressin* | 6 |
| COLACE | 10 | Desogest/Eth Est & Eth Estradiol | 4 |
| Colchicine | 13 | Desogestral & Ethinyl Estradiol | 4 |
| COLCRYS | 13 | Desonide* | 19 |
| COLESTID | 8 | DESOWEN | 19 |
| Colestipol* | 8 | Dexamethasone* | 4 |
| Collagenase | 19 | Dexamethasone* | 17 |
| COMBIVENT | 9 | DIABETA | 5 |
| COMTAN | 14 | DIAMOX | 8 |
| Condoms | 20 | Diclofenac* | 13 |
| CONDYLOX | 19 | Dicloxacillin Sodium* | 1 |
| Conjugated Estrogens & Medroxy* | 4 | Dicyclomine* | 11 |
| COPAXONE | 4 | DIFLUCAN | 2 |
| CORDARONE | 7 | Digoxin* | 6 |
| COREG | 6 | DILACOR/XR | 7 |
| CORTEF | 4 | DILANTIN | 14 |
| Cortisone* | 4 | DILAUDID | 13 |
| CORTISPORIN | 17 | Diltiazem* | 7 |
| CORTISPORIN OTIC | 18 | DIOVAN | 7 |
| CORTISPORIN TOPICAL | 18 | DIOVAN HCT | 7 |
| COUMADIN | 16 | Diphenhydramine* | 9 |
| COZAAR | 7 | Diphenhydramine* | 12 |
| CREON | 11 | Diphenoxylate w/ Atropine* | 10 |
| CRESTOR | 8 | Dipivefrin* | 18 |
| Cromolyn (inhalation) | 9 | Dipyridamole* | 6 |
| Cromolyn (nasal)* | 9 | Disopyramide* | 7 |
| CRYSSELLE | 4 | Disposable Needles & Syringes* | 20 |
| CUPRIMINE | 20 | Disulfiram* | 17 |
| CVS COLD ALLERGY DM ELIXIR | 10 | DITROPAN | 11 |
| CVS COLD ALLERGY ELIXIR | 10 | DIURIL | 8 |
| CVS COUGH FORMULA D | 10 | Docusate Sodium* | 10 |
| CVS INFANT DCON & COUGH | 10 | Donepezil* | 17 |
| CVS TRIACTING MULTI-SYMPATOM | 10 | Dorzolamide* | 18 |
| Cyanocobalamin* | 16 | DOVONEX | 19 |
| Cyclobenzaprine* | 14 | Doxazosin* | 7 |
| Cyclophosphamide* | 3 | Doxycycline* | 1 |
| Cycloserine | 2 | DRISDOL | 15 |
| Cyclosporine Microsize* | 20 | Drosiprone & Ethinyl Estradiol* | 4 |

| <u>Product Name</u> | <u>Page</u> | <u>Product Name</u> | <u>Page</u> |
|---------------------------------|-------------|---------------------------------|-------------|
| DUETACT | 5 | EXELON | 17 |
| DULCOLAX | 10 | Exenatide | 5 |
| DUONEB | 9 | Ezetimibe | 8 |
| DURAGESIC | 13 | Ezetimibe & Simvastatin | 8 |
| DURATUSS | 10 | Famotidine* | 11 |
| E.E.S. | 1 | FEIBA VH | 16 |
| ECOTRIN | 12 | FELDENE | 13 |
| EFUDEX | 3 | Felodipine* | 7 |
| EFUDEX | 19 | FEMARA | 3 |
| ELDEPRYL | 14 | Fenofibrate | 8 |
| ELIDEL | 19 | Fenofibrate micronized | 8 |
| ELIMITE | 19 | Fenofibric acid | 8 |
| Enalapril* | 7 | Fenoprofen* | 13 |
| ENBREL | 20 | Fentanyl* | 13 |
| Enoxaparin* | 16 | FEOSOL | 16 |
| ENSURE | 15 | FERGON | 16 |
| Entacapone | 14 | Ferrous Gluconate* | 16 |
| Epinephrine | 8 | Ferrous Sulfate* | 16 |
| Epinephrine | 9 | Fexofenadine* | 9 |
| EPI-PEN/EPI-PEN JR | 8 | Fexofenadine / Pseudoephedrine* | 9 |
| EPI-PEN/EPI-PEN JR | 9 | FIBERCON | 10 |
| Epoetin Alfa | 16 | Filgrastim | 16 |
| EPOGEN | 16 | Finasteride* | 11 |
| Ergocalciferol* | 15 | FIORICET | 12 |
| Ergoloid mesylates* | 14 | FIORINAL | 12 |
| ERGOMAR | 14 | FLAGYL | 2 |
| Ergotamine tartrate | 14 | Flavoxate* | 11 |
| Ergotamine w/ Caffeine | 14 | Flecainide* | 7 |
| Erlotinib | 4 | FLEXERIL | 14 |
| ERRIN | 4 | FLOMAX | 7 |
| ERYGEL | 19 | FLOXIN | 9 |
| ERY-TAB | 1 | FLORINEF | 4 |
| ERYTHROCIN | 1 | FLOVENT HFA | 9 |
| Erythromycin Base* | 1 | FLOXIN | 18 |
| Erythromycin Estolate* | 1 | Fluconazole* | 2 |
| Erythromycin Ethylsuccinate* | 1 | Fludrocortisone* | 4 |
| Erythromycin Gel* | 19 | Flunisolide* | 9 |
| Erythromycin ophthalmic* | 17 | Fluocinonide* | 19 |
| Erythromycin Stearate* | 1 | Fluocinonide Acetonide* | 19 |
| Erythromycin / Sulfisoxazole* | 2 | Fluorouracil* | 3 |
| Esterified Estrogens | 4 | Fluorouracil* | 19 |
| ESTRACE | 4 | Flurbiprofen* | 13 |
| Estradiol* | 4 | Flurbiprofen* | 18 |
| Estradiol Patch* | 4 | Flutamide* | 3 |
| Estrogens, Conjugated | 4 | Fluticasone | 9 |
| Etanercept | 20 | Fluvastatin* | 8 |
| Ethambutol* | 2 | Folic Acid & Vitamin B Complex* | 15 |
| Ethionamide | 2 | Folic Acid* | 16 |
| Ethosuximide* | 14 | FORTEO | 6 |
| Ethinodiol Diacet & Eth Estrad* | 4 | FOSAMAX | 6 |
| Etodolac* | 13 | FOSAMAX PLUS D | 6 |
| Etonogestrel-Ethinyl Estradiol | 4 | Fosinopril* | 7 |
| Etoposide* | 3 | FURADANTIN | 11 |
| EVISTA | 6 | Furosemide* | 8 |

| <u>Product Name</u> | <u>Page</u> | <u>Product Name</u> | <u>Page</u> |
|-------------------------------|-------------|-------------------------|-------------|
| Galantamine* | 17 | Hydroxocobalamin* | 16 |
| Ganciclovir* | 2 | Hydroxychloroquine* | 2 |
| GANTRISIN | 2 | Hydroxyurea* | 4 |
| GARAMYCIN | 2 | Hyoscyamine* | 11 |
| Gatifloxacin | 17 | Hyoscyamine Sulfate* | 11 |
| Gemfibrozil* | 8 | HYPOLET | 20 |
| GENTAK | 17 | HYTONE | 19 |
| Gentamicin Sulfate* | 2 | HYTRIN | 7 |
| Gentamicin Sulfate* | 17 | HYZAAR | 7 |
| Gentamicin Topical* | 18 | Ibandronate* | 6 |
| Glatiramer acetate | 4 | Ibuprofen* | 13 |
| Glimepiride* | 5 | IMDUR | 6 |
| Glipizide* | 5 | IMITREX | 14 |
| GLUCAGON | 5 | IMODIUM | 10 |
| GLUCOFILM | 19 | IMURAN | 20 |
| GLUCOMETER | 20 | INCIVEK | 3 |
| GLUCOPHAGE | 5 | Indapamide* | 8 |
| Glucose Blood* | 19 | INDERAL/LA | 6 |
| Glucose Urine Test* | 19 | INDERIDE | 7 |
| GLUCOTROL/XL | 5 | INDOCIN | 13 |
| Glyburide* | 5 | Indomethacin* | 13 |
| Glycerin* | 10 | Infant Foods | 15 |
| Glycerin supp.* | 8 | Insulin Aspart | 5 |
| GLYNASE | 5 | Insulin Glargine | 5 |
| GOLYTELY | 10 | Insulin Isophane | 5 |
| GRIFULVIN V | 2 | Insulin Lispro | 5 |
| Griseofulvin Microsize | 2 | Insulin Pen Needles | 20 |
| Griseofulvin Ultramicrosized | 2 | Insulin Reg & Isophane | 5 |
| GRIS-PEG | 2 | Insulin Reg & NPH | 5 |
| Guaifenesin* | 10 | Insulin Regular | 5 |
| Guaifenesin/DM* | 10 | INTAL | 9 |
| Guanfacine* | 7 | Interferon Alfa-2A | 4 |
| Guanfacine | 17 | Interferon Alfa-2B | 4 |
| GYNAZOLE-1 | 12 | Interferon Alfa-n3 | 4 |
| HABITROL | 17 | Interferon Beta-1a | 4 |
| HUMALOG | 5 | Interferon Beta-1b | 4 |
| HUMATROPE | 6 | INTRON-A | 4 |
| HUMIRA | 20 | INTUNIV | 17 |
| HUMULIN 50/50 | 5 | Ipecac* | 19 |
| HUMULIN 70/30 | 5 | Ipratropium* | 9 |
| HUMULIN N | 5 | Irbesartan* | 7 |
| HUMULIN R | 5 | Irbesartan & HCTZ | 7 |
| HYCOTUSS | 10 | Isoniazid* | 2 |
| HYDERGINE | 14 | ISOPTO ATROPINE | 18 |
| Hydralazine* | 7 | ISOPTO-CARPINE | 18 |
| Hydralazine & HCTZ* | 8 | ISORDIL/ISORDIL TEMBIDS | 6 |
| HYDREA | 4 | Isosorbide Dinitrate* | 6 |
| Hydrochlorothiazide* | 8 | Isosorbide Mononitrate* | 6 |
| Hydrocodone-GG* | 10 | Itraconazole* | 2 |
| Hydrocortisone w/Acetic Acid* | 18 | KAPVAY | 17 |
| Hydrocortisone* | 4 | KARIVA | 4 |
| Hydrocortisone* | 18 | KAYEXALATE | 20 |
| Hydrocortisone* | 19 | KEFLEX | 1 |
| Hydromorphone* | 13 | KENALOG | 19 |

| <u>Product Name</u> | <u>Page</u> | <u>Product Name</u> | <u>Page</u> |
|-------------------------------|-------------|----------------------------|-------------|
| KERALAC | 19 | LORTAB | 13 |
| KERALAC NAILSTIK | 19 | losartan potassium* | 7 |
| Ketoconazole* | 2 | losartan potassium & HCTZ* | 7 |
| KETOSTIX | 19 | LOTENSIN | 7 |
| KLOR-CON | 15 | LOTREL | 7 |
| Labetalol* | 6 | LOTRIMIN | 18 |
| LAC-HYDRIN | 19 | lovastatin* | 8 |
| Lactulose* | 10 | LOVAZA | 8 |
| LAMISIL | 2 | LOVENOX | 16 |
| Lancets* | 20 | LUPRON | 3 |
| Lancet Device | 20 | LURIDE | 15 |
| LANOXIN | 6 | LYSODREN | 4 |
| Lansoprazole* | 11 | MAALOX | 10 |
| LANTUS | 5 | MACROBID | 11 |
| LASIX | 8 | MANDELAMINE | 11 |
| Latanoprost* | 18 | MATERNA | 15 |
| LESCOL | 8 | MATULANE | 4 |
| Letrozole* | 3 | MAXAIR AUTOHALER | 9 |
| LEUCOVORIN | 16 | MAXALT | 14 |
| Leucovorin Calcium* | 16 | MAXITROL | 17 |
| LEUKERAN | 3 | MAXZIDE | 8 |
| Leuprolide | 3 | MEBARAL | 12 |
| Levofloxacin* | 1 | Mebendazole* | 2 |
| Levonorgestrel* | 5 | Meclizine* | 11 |
| Levonorgestrel-Eth Estradiol | 4 | MEDROL | 4 |
| LEVORA | 4 | Medroxyprogesterone* | 5 |
| Levothyroxine* | 5 | Medroxyprogesterone Depot* | 5 |
| LEVOXYL | 5 | MEGACE | 3 |
| LEVSIN | 11 | Megestrol* | 3 |
| LEVSINEX | 11 | Meloxicam* | 13 |
| LIDEX | 19 | Melphalan | 3 |
| Lidocaine* | 14 | Memantine | 17 |
| Lidocaine viscous* | 19 | MENEST | 4 |
| LIDODERM PATCHES | 14 | Meperidine* | 13 |
| Lindane* | 19 | Mephobarbital | 12 |
| Liothyronine* | 5 | Mephyton | 15 |
| LIPITOR | 8 | Mercaptopurine* | 3 |
| LIPOFEN | 8 | Mesalamine | 11 |
| Liraglutide | 5 | MESTINON | 15 |
| Lisinopril* | 7 | Metformin* | 5 |
| Lisinopril & HCTZ* | 7 | Methadone* | 13 |
| Lodoxamine | 17 | Methazolamide* | 8 |
| LOFENALAC | 15 | Methenamine Mandelate* | 11 |
| LOFIBRA | 8 | METHERGINE | 5 |
| LOMOTIL | 10 | Methimazole* | 5 |
| Lomustine | 3 | Methocarbamol* | 14 |
| Loperamide* | 10 | Methocarbamol w/Aspirin* | 14 |
| LOPID | 8 | Methotrexate* | 3 |
| LOPRESSOR | 6 | Methotrexate* | 13 |
| LOPRESSOR HCT | 7 | Methyclothiazide* | 8 |
| LORABID SUSPENSION | 1 | Methylpopa* | 7 |
| Loracarbef | 1 | Methylpopa & HCTZ* | 7 |
| Loratadine* | 9 | Methylethergonovine | 5 |
| Loratadine / Pseudoephedrine* | 9 | Methylprednisolone* | 4 |

| <u>Product Name</u> | <u>Page</u> | <u>Product Name</u> | <u>Page</u> |
|-------------------------------|-------------|----------------------------------|-------------|
| Methyltestosterone | 4 | MYSOLINE | 17 |
| Metoclopramide* | 11 | Nafarelin | 6 |
| Metolazone* | 8 | NALFON | 13 |
| Metoprolol & HCTZ* | 7 | Naltrexone* | 13 |
| Metoprolol Succinate* | 6 | NAMENDA | 17 |
| Metoprolol Tartrate* | 6 | Naphazoline* | 18 |
| METROGEL | 18 | NAPHCN | 18 |
| METROGEL-VAGINAL | 12 | NAPROSYN | 13 |
| Metronidazole* | 2 | Naproxen* | 13 |
| Metronidazole* | 12 | Naproxen Sodium* | 13 |
| Metronidazole | 18 | NASACORT AQ | 9 |
| MEVACOR | 8 | NASALCROM | 9 |
| Mexiletine* | 7 | NASALIDE | 9 |
| MIACALCIN INJ | 6 | NASONEX | 9 |
| MIACALCIN NASAL | 6 | NECON | 4 |
| Miconazole* | 2 | NECON 7/7/7 | 4 |
| Miconazole* | 12 | Neomycin-Bac Zn-Polymyxin* | 17 |
| Miconazole* | 18 | Neomycin-Bacitracin-Polymyxin* | 18 |
| MICROGESTIN FE | 4 | Neomycin-Poly-Dexamethasone* | 17 |
| MICRO-K | 15 | Neomycin-Polymy-Gramicidin* | 17 |
| Milnacipran | 14 | Neomycin-Polymyxin-HC Opth* | 17 |
| MINIPRESS | 7 | Neomycin-Polymyxin-HC Otic* | 18 |
| Minoxidil* | 7 | Neomycin-Polymyxin-HC Topical* | 18 |
| Mitotane | 4 | Neomycin Sulfate* | 2 |
| MOBIC | 13 | Neomycin Sulfate topical* | 18 |
| Mometasone furoate | 9 | NEORAL | 20 |
| MONISTAT | 2 | NEOSPORIN | 17 |
| MONISTAT | 12 | NEOSPORIN | 18 |
| MONISTAT | 18 | NEPHROCAPS | 15 |
| MONOPRIL | 7 | NEUPOGEN | 16 |
| Montelukast Sodium* | 10 | NEXAVAR | 4 |
| Morphine Sulfate SR* | 13 | Niacin & Lovastatin | 8 |
| Morphine Sulfate* | 13 | Niacin* | 8 |
| MOTRIN | 13 | Niacin* | 15 |
| Moxifloxacin | 1 | Niacin CR | 8 |
| Moxifloxacin HCL | 17 | NIASPAN | 8 |
| MS CONTIN | 13 | NICODERM/NICODERM CQ | 17 |
| MSIR | 13 | Nicotine* | 17 |
| MUCOMYST | 9 | NICOTROL | 17 |
| Multiple Vitamin* | 15 | Nifedipine* | 7 |
| Multiple Vitamin w/ Minerals* | 15 | NITROBID | 6 |
| Mupirocin* | 18 | NITRODUR | 6 |
| MYAMBUTOL | 2 | Nitrofurantoin* | 11 |
| MYCELEX | 12 | Nitrofurantoin Macrocrystals* | 11 |
| MYCELEX TROCHE | 18 | Nitroglycerin (oral)* | 6 |
| MYCIBUTIN | 2 | Nitroglycerin (topical)* | 6 |
| Mycophenolate Mofetil* | 20 | NITROSTAT | 6 |
| Mycophenolate Sodium | 20 | NIX | 19 |
| MYCOSTATIN | 2 | NIZORAL | 2 |
| MYDFRIN | 18 | NOLVADEX | 3 |
| MYFORTIC | 20 | Norelgestromin-Ethinyl Estradiol | 4 |
| MYLANTA | 10 | Norethindrone* | 4 |
| MYLERAN | 3 | Norethindrone* | 5 |
| MYSOLINE | 14 | Norethindrone-Ethinyl Estrad | 4 |

| <u>Product Name</u> | <u>Page</u> | <u>Product Name</u> | <u>Page</u> |
|-----------------------------------|-------------|-------------------------------------|-------------|
| Norgestimate & Ethinyl Estradiol* | 4 | Pediatric Multivitamins w/Fluoride* | 15 |
| Norgestrel & Ethinyl Estradiol* | 4 | Pediatric Multivitamins w/Iron* | 15 |
| NORPACE/CR | 7 | Pediatric Vitamins* | 15 |
| NORTREL | 4 | PEGASYS | 3 |
| NORTREL 7/7/7 | 4 | PEG-Electrolyte* | 10 |
| NORVASC | 7 | Peginterferon | 3 |
| NOVOLIN 70/30 | 5 | PEG-INTRON | 3 |
| NOVOLIN N | 5 | PEN VEE K | 1 |
| NOVOLIN R | 5 | Penicillamine | 20 |
| NOVOLOG | 5 | Penicillin G Benzathine | 1 |
| Nutritional Supplements | 15 | Penicillin V Potassium* | 1 |
| NUVARING | 4 | PENTASA | 11 |
| Nystatin* | 2 | Pentoxifylline* | 16 |
| Nystatin* | 18 | PEPCID | 11 |
| Nystatin (local)* | 18 | PEPTO-BISMOL | 10 |
| Nystatin (vaginal)* | 12 | PERCOCET | 13 |
| Nystatin-Triamcinolone* | 18 | PERCODAN | 13 |
| Octreotide Acetate* | 10 | Permethrin* | 19 |
| OCUFEN | 18 | PERSANTINE | 6 |
| Ofloxacin* | 18 | Phenazopyridine* | 12 |
| Olopatadine | 17 | PHENERGAN | 9 |
| Omega-3-acid ethyl esters | 8 | Phenobarbital* | 12 |
| Omeprazole* | 11 | Phenylephrine* | 18 |
| OMNICEF | 1 | Phenyl-Free* | 15 |
| Ondansetron | 11 | Phenytoin* | 14 |
| ONE-A-DAY | 15 | PHOSLO | 15 |
| ONE-A-DAY KIDS COMPLETE | 15 | Pilocarpine* | 18 |
| ORACIT | 12 | Pimecrolimus | 19 |
| ORACIT | 15 | PIN-X | 2 |
| Oral Electrolytes* | 15 | Pioglitazone* | 5 |
| ORAMORPH SR | 13 | Pioglitazone-Glimpiride | 5 |
| ORTHO EVRA PATCH | 4 | Pioglitazone-Metformin | 5 |
| ORTHO TRI CYCLEN | 4 | Pirbuterol | 9 |
| ORTHO TRI-CYCLEN LO | 4 | Piroxicam* | 13 |
| ORTHOCEPT | 4 | PLAN-B | 5 |
| OS-CAL | 10 | PLAQUENIL | 2 |
| OS-CAL | 15 | PLAVIX | 16 |
| Oseltamivir phosphate | 2 | PLENDIL | 7 |
| OXACILLIN | 1 | Podofilox | 19 |
| Oxybutynin* | 11 | Polycarbophil Calcium* | 10 |
| Oxycodone* | 13 | Polymixin B-Trimethoprim* | 17 |
| Oxycodone CR* | 13 | POLYSPORIN | 17 |
| Oxycodone w/ Acetaminophen* | 13 | POLYTRIM | 17 |
| Oxycodone w/ Aspirin* | 13 | POLY-VI-FLOR | 15 |
| OXYCONTIN | 13 | Potassium Chloride Capsule* | 15 |
| OXYIR | 13 | Potassium Chloride Liquid* | 15 |
| Palivizumab | 3 | Potassium Chloride Tablet* | 15 |
| Pantoprazole* | 11 | PRADAXA | 16 |
| PARLODEL | 14 | PRAVACHOL | 8 |
| PATANOL | 17 | Pravastatin* | 8 |
| PEDIACARE INFANT | 7 | Prazosin* | 10 |
| PEDIALYTE | 15 | PRECOSE | 5 |
| PEDIAPRED | 4 | PRED FORTE/MILD | 17 |
| PEDIASURE | 15 | Prednisolone* | 4 |

| <u>Product Name</u> | <u>Page</u> | <u>Product Name</u> | <u>Page</u> |
|---------------------------------|-------------|----------------------------------|-------------|
| Prednisolone Acetate* | 17 | Pyrimethamine | 3 |
| Prednisolone Na Phosphate* | 4 | QUESTRAN/LIGHT | 8 |
| Prednisone* | 4 | Quinapril* | 7 |
| PRELONE | 4 | Quinidine Sulfate* | 7 |
| PREMARIN | 4 | QVAR | 9 |
| PREMPRO | 4 | Raloxifene | 6 |
| Prenatal MV & Min w/FE-FA* | 15 | Ramipril* | 7 |
| Prenatal Vitamins* | 15 | Ranitidine* | 11 |
| PRENATAL-1 | 15 | RAPAMUNE | 20 |
| PREVACID, OTC | 11 | RAZADYNE | 17 |
| PRILOSEC OTC | 11 | RAZADYNE ER | 17 |
| Primidone* | 14 | REBETOL | 3 |
| Primidone* | 17 | REBIF | 4 |
| PROAIR HFA | 9 | RECOMBINATE | 16 |
| PRO-BANTHINE | 11 | REGLAN | 11 |
| Probenecid* | 13 | RELENZA | 2 |
| Procainamide* | 7 | REQUIP | 14 |
| Procarbazine | 7 | Reserpine* | 7 |
| PROCARDIA XL | 4 | RETIN-A | 19 |
| Prochlorperazine* | 7 | REVIA | 13 |
| Prochlorperazine* | 11 | RHEUMATREX | 3 |
| PROCRIT | 12 | RHEUMATREX | 13 |
| PROCTOCREAM | 16 | Ribavirin* | 3 |
| PROGRAF | 18 | Rifabutin | 2 |
| PROLOPRIM | 20 | RIFADIN | 2 |
| PROLOPRIM | 2 | Rifampin* | 2 |
| Promethazine* | 11 | RILUTEK | 15 |
| PRONESTYL | 9 | Riluzole | 15 |
| Propafenone* | 7 | Risedronate | 6 |
| Propantheline Bromide* | 7 | Rivastigmine* | 17 |
| PROPINE | 11 | Rizatriptan tablets | 14 |
| Propoxyphene w/ APAP* | 18 | ROBAXIN | 14 |
| Propranolol & HCTZ* | 13 | ROCALTROL | 15 |
| Propranolol* | 7 | ROCEPHIN | 1 |
| Propylthiouracil* | 6 | ROFERON-A | 4 |
| PROSCAR | 5 | ROMYCIN | 17 |
| PROSTEP | 11 | Ropinirole* | 14 |
| PROTONIX | 17 | Rosiglitazone Maleate | 5 |
| PROVENTIL HFA | 11 | Rosiglitazone Maleate-Glimperide | 5 |
| PROVERA | 9 | Rosiglitazone Maleate-Metformin | 5 |
| Pseudoephed/Brompheniramine-DM* | 5 | Rosuvastatin Calcium | 8 |
| Pseudoephedrine HCL soln* | 10 | ROWASA | 11 |
| Pseudoephedrine HCL* | 10 | ROXICODONE | 13 |
| Pseudoephedrine/Chlorphen-DM* | 9 | RYTHMOL | 7 |
| Pseudoephedrine-DM* | 10 | Salmeterol | 9 |
| Pseudoephedrine-GG* | 10 | Salmeterol-Fluticasone | 9 |
| PULMICORT FLEXHALER | 10 | Salsalate* | 12 |
| PULMICORT RESPULES | 9 | SANDOSTATIN | 10 |
| PURINETHOL | 9 | SANTYL | 19 |
| Pyrantel Pamoate* | 3 | SAVELLA | 14 |
| Pyrazinamide* | 2 | Selegiline* | 14 |
| PYRIDIUM | 2 | SEROMYCIN | 2 |
| Pyridostigmine* | 12 | SERVENT DISKUS | 9 |
| | 15 | SILVADENE | 19 |

| <u>Product Name</u> | <u>Page</u> | <u>Product Name</u> | <u>Page</u> |
|---------------------------------|-------------|----------------------------------|-------------|
| Silver Sulfadiazine* | 19 | Terazosin* | 7 |
| Simvastatin* | 8 | Terbinafine* | 2 |
| SINEMET/CR | 14 | Teriparatide | 6 |
| SINGULAIR | 10 | Tetracycline* | 1 |
| Sirinlimus | 20 | THEO-24 | 10 |
| Sodium Citrate & Citric Acid* | 12 | Theophylline* | 10 |
| Sodium Citrate & Citric Acid* | 15 | Thioguanine | 3 |
| Sodium Fluoride* | 15 | THROMBAT III | 16 |
| Sodium Polystyrene Sulfonate* | 20 | THROMBIN | 16 |
| Sodium Sulfacetamide* | 17 | Thyroid* | 5 |
| Sodium Sulfacetamide* | 19 | Timolol* | 6 |
| Somatropin | 6 | Timolol* | 17 |
| Sorafenib | 4 | TIMOPTIC | 17 |
| Sotalol* | 6 | Tiotropium | 9 |
| SPIRIVA | 9 | TOPROL XL | 6 |
| Spironolactone* | 8 | Tramadol* | 13 |
| Spironolactone & HCTZ* | 8 | Tramadol / APAP* | 13 |
| SPORANOX | 2 | TRANDATE | 6 |
| SPRINTEC | 4 | TRECATOR | 2 |
| SUBOXONE | 13 | TRENTAL | 16 |
| SUBUTEX | 13 | Tretinoin* | 19 |
| Succimer | 20 | TREXIMET | 14 |
| Sucralfate* | 11 | Triamcinolone* | 9 |
| Sulfacetamide Sod-Prednisolone* | 17 | Triamcinolone Acetonide* | 19 |
| Sulfadiazine* | 2 | Triamcinolone Ace. In Orabase* | 19 |
| Sulfanilamide | 12 | Triamterene & HCTZ* | 8 |
| Sulfasalazine* | 2 | TRICOR | 8 |
| Sulfasalazine* | 11 | Trifluridine | 17 |
| Sulfisoxazole* | 2 | TRIGLIDE | 8 |
| Sulindac* | 13 | TRILIPIX | 8 |
| Sumatriptan | 14 | Trimethoprim* | 2 |
| Sumatriptan-Naproxen | 14 | Trimethoprim* | 11 |
| SUMYCIN | 1 | Trimethoprim / Sulfamethoxazole* | 2 |
| SUPRAX | 1 | TRI-NORINYL | 4 |
| SYMBICORT | 9 | Triple Sulfas Vaginal* | 12 |
| SYMMETREL | 3 | TRIVORA | 4 |
| SYMMETREL | 14 | TRUSOPT | 18 |
| SYNAGIS | 3 | TYLENOL | 12 |
| SYNALAR | 19 | TYLENOL / CODEINE | 13 |
| SYNAREL | 6 | ULTRACET | 13 |
| SYNTHROID | 5 | ULTRAM | 13 |
| TABLOID | 3 | UNIPHYL | 10 |
| Tacrolimus* | 20 | Urea 35% | 19 |
| TAMBOCOR | 7 | Urea 50% | 19 |
| TAMIFLU | 2 | URECHOLINE | 11 |
| Tamoxifen* | 3 | URISPAS | 11 |
| Tamsulosin* | 7 | Valsartan | 7 |
| TAPAZOLE | 5 | Valsartan & HCTZ | 7 |
| TARCEVA | 4 | Varenicline Tartarate | 17 |
| Telaprevir | 3 | VASOTEC | 7 |
| TEMOVATE | 19 | VENTOLIN HFA | 9 |
| TENEX | 7 | VEPESID | 3 |
| TENORETIC | 7 | Verapamil* | 7 |
| TENORMIN | 6 | VIBRAMYCIN | 1 |

| <u>Product Name</u> | <u>Page</u> | <u>Product Name</u> | <u>Page</u> |
|----------------------|-------------|---------------------|-------------|
| VICODIN | 13 | | |
| VICTOZA | 5 | | |
| VICTRELIS | 3 | | |
| Vidarabine | 17 | | |
| VIGAMOX | 17 | | |
| VIOKACE | 11 | | |
| VIRA-A | 17 | | |
| VIROPTIC | 17 | | |
| Vitamin A* | 15 | | |
| VITAMIN B-12 | 16 | | |
| VITAMIN K | 15 | | |
| VIVONEX | 15 | | |
| VOLTAREN | 13 | | |
| VYTORIN | 8 | | |
| Warfarin Sodium* | 16 | | |
| XALATAN | 18 | | |
| XELODA | 3 | | |
| XYLOCAINE VISCOUS | 19 | | |
| YASMIN | 4 | | |
| YAZ | 4 | | |
| Zanamivir | 2 | | |
| ZANTAC | 11 | | |
| ZARONTIN | 14 | | |
| ZAROXOLYN | 8 | | |
| ZESTORETIC | 7 | | |
| ZESTRIL | 7 | | |
| ZETIA | 8 | | |
| ZITHROMAX | 1 | | |
| ZOCOR | 8 | | |
| ZOFRAN | 11 | | |
| Zolmitriptan tablets | 14 | | |
| ZOMIG | 14 | | |
| ZORPRIN | 12 | | |
| ZOVIA | 4 | | |
| ZOVIRAX | 3 | | |
| ZOVIRAX TOPICAL | 19 | | |
| ZYLOPRIM | 13 | | |
| ZYMAXID | 17 | | |
| ZYRTEC | 9 | | |